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Abstract 
Current conventional epilepsy treatments do not always aim to improve epilepsy 
comorbidities. For a treatment to be effective, is not necessary for it to keep the patient 
seizure-free; it is sufficient to show improvement in functions to help people who suffer 
from epilepsy to become more independent and productive in life.   There is an urgent need 
to explore non- pharmaceutical/non-invasive interventions that can help in that regard.  The 
earlier patients are treated with this condition, the more likely it is to prevent severe 
disabilities over time.  
Neurofeedback is a self-modulatory brain activity oscillatory intervention that 
previous researchers have found to reduce seizure frequency in patients with epilepsy.  The 
aim of this work was to compare two Neurofeedback techniques that have shown some 
efficacy in improving symptoms in epilepsy.  The novelty of this study is to explore further 
and included clinical, neurophysiological and cognitive outcomes in order to assess in more 
detail the effectiveness epilepsy comorbidities.  
Forty-four patients, between the ages of 12 and 18 years, and diagnosed with focal 
epilepsy, divided randomly in to three groups: sensorimotor rhythm (SMR) training, slow 
cortical potential (SCP) training, and control.  The patients completed 25 sessions of 
intervention.  
The results showed that the SMR group training had an advantage in improving 
reaction time compared with SCP and control.  Regression analysis revealed a significant 
correlation between the patients who learned to modify their brain activity in the SMR 
EPILEPSY AND NEUROFEEDBACK  8 
group and improving reaction time in two different tasks.  In addition, the quality of life 
scale significantly improved in all three groups. 
The study supplies preliminary data to support that SMR neurofeedback training as 
an intervention should further be explored as a therapeutic option for children who suffer 
from focal epilepsy.  
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Chapter 1     Overview 
 
The understanding of the human brain is one of the more complex subjects in 
science, philosophy, and even spirituality.  Scientists are accelerating the pace of 
discoveries each day due to advancements in technology, yet we still are far from a 
complete comprehension of the mechanisms of the integrative function of the human brain.  
Many neurological and psychiatric conditions are still considered mysterious entities and, 
in some cases, their unknown etiology makes it even harder to diagnose and select the most 
effective treatment and interventions.  Furthermore, neurological and psychiatric drug trials 
are failing phase III studies, and the number of patients searching for alternative therapeutic 
options is increasing every day.  For these reasons, there is a deep interest within 
neuroscience to explore and understand better the mechanisms and efficacy of interventions 
that could have a positive effect on brain disorders.  This study explored the use of newer 
interventions applied to one of the more complex and stigmatized neurological disorders.  
These interventions are worth studying because they could provide further therapeutic 
options to people suffering from this condition.   
The following sections feature a thorough review of the pathology of epilepsy, its 
complexity, and the stigma attached to this neurological disease.  This study introduces the 
background of a condition with a high incidence in the population, which is associated with 
a heavy burden to society due to the significant incidence of disability that is usually 
associated with epilepsy.  Among the difficulties for patients suffering from epilepsy are 
the iatrogenic effects of the pharmacological regimen required to stabilize the condition. 
EPILEPSY AND NEUROFEEDBACK  17 
The multi-drug approach promotes the development of severe comorbidities (cognitive, 
psychological and neurological), while decreasing quality of life.   
Conventional treatments for epilepsy focus on pharmacological interventions, while 
finding the right drug, or the combination of them, to decrease seizure activity is the main 
goal for many medical specialists.  Unfortunately, not all individuals with epilepsy respond 
adequately to conventional pharmacological treatments.   
It is important to note that, in clinical experience, no pharmacological intervention 
aims to improve the comorbidities associated with the side effects of drug treatment, which 
contributes to the dysfunction of those being treated for epilepsy.  These drug iatrogenic 
effects place heavy burden on the personal, social and emotional life of those being treated.  
It is, therefore of interest to explore innovative non-pharmacological interventions that 
could improve not only seizure control but also the comorbidities (clinical, cognitive and 
neurophysiological) present in individuals with epilepsy.  
Neurofeedback is a form of brain computer interphase intervention studied for the 
last four decades.  Sterman et al found the first condition tested using this intervention was 
epilepsy in early 1970s, and showed preliminary positive results in seizure control 
(Sterman, Wyrwicka, & Howe, 1969).  Researchers were enthusiastic about the efficacious 
effects of this intervention.  Unfortunately, after some initial trials, interest in studying 
neurofeedback methods and methodologies decreased as researchers began focusing more 
on behavioral conditions, leaving a gap between neurological research and neurofeedback 
applications.  Another reason why research interest waned in neurological application of 
neurofeedback was the complexity of designing appropriate control randomized studies in 
EPILEPSY AND NEUROFEEDBACK  18 
epilepsy.  Additionally, few researchers in the medical community were interested in 
exploring non-pharmacological interventions, which led to a lack of financial support, 
making it harder for established scientists to continue in this line of research. 
Some professionals practicing in the field of neurological rehabilitation experience 
constant frustration and concern for patients with epilepsy, considering the various 
comorbidities and the side effects of the drugs as a part of their treatment regimen.  
Individuals suffering from epilepsy often indicate that the seizures are less of an issue in 
their lives compared with the comorbidities and how there are few interventions to help 
them in that regard. 
The unique contribution of this study is the evaluation of the physiological and 
behavioural effects of neurofeedback for the treatment of children and adolescents with 
focal epilepsy.  There are two neurofeedback modalities—sensorimotor (SMR) and slow 
cortical potentials (SCP)—that have been employed and studied that have demonstrated 
some beneficial effects in epilepsy.  This study compared these modalities and evaluated 
their impact in young patients with focal epilepsy.  Of special interest is that it has been 
well reported that the earlier a patient receives intervention with resultant improved 
function, the better  the prognosis (Cioni, Inguaggiato, & Sgandurra, 2016).  
This study comprehensively and critically examined the available literature to 
provide the necessary background to better understand the epilepsies in the context of 
neurofeedback applications.  It begins with a review of epilepsy as a pathological entity, the 
complexity of the neurophysiological components, and the basis of the complex 
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comorbidities.  The different types of epilepsy and etiologies are reviewed, but this study 
focuses on patients with focal epilepsy.   
The statement of purpose of this study was to compare two neurofeedback 
modalities and explore the clinical, neurophysiological and cognitive outcomes of each in 
order to better inform decisions about which intervention is more appropriate for children 
who suffer from focal epilepsy.  
 
Research Aim, Objectives and Hypotheses 
The aim of this study was to examine two neurofeedback interventions to explore 
their clinical, neurophysiological, and cognitive effects among children with focal epilepsy.   
The research objectives were 
1. To examine the clinical, neurophysiological, and cognitive effects of 
neurofeedback on children with focal epilepsy. 
2. To explore differences between neurofeedback techniques (SMR or SCP) on 
clinical, neurophysiological, and cognitive functions in children with focal 
epilepsy.  
3. To examine which area of evaluation (clinical, neurophysiological and 
cognitive) has more effect using neurofeedback on children with focal epilepsy. 
4. To explore if there is a specific type of neurofeedback from which children with 
epilepsy will benefit the most.  
5. To explore if there are associations between how the participant learn with 
neurofeedback and specific variables.  
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The research hypotheses were the following: 
1. The type of intervention, active intervention (SMR or SCP), would provide 
significantly greater effects in clinical, neurophysiological, and cognitive 
functions of epilepsy relative to controls.   
2. Significant differences exist between the means of the clinical, 
neurophysiological, and cognitive measures across three-time intervals (at the 
beginning of intervention (baseline), after the last session of intervention was 
concluded, and three months after the conclusion of the intervention. 
3. Significant differences exist between the means of the groups (SMR, SCP, and 
control). 
 
The novelty of the present study is the exploratory outcome of variables that include 
clinical, neurophysiological and cognitive functions that are part of comorbidities in 
epilepsy. This study compared two neurofeedback modalities that are recognized as 
possibly effective in epilepsy.  
Also, the age of the participants (children) is something that this study offers, as 
most of previous research done with neurofeedback and epilepsy is on adult population.   
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Chapter 2    Epilepsy Background 
Epilepsy is considered one of the oldest neurological conditions and is characterized 
by recurrent seizures.  It is important to define the difference between a seizure and 
epilepsy (Howell, Harvey, & Archer, 2016).  A seizure is a clinically discernible event that 
results from the synchronous and excessive discharge of neurons in the cerebral cortex.  It 
has the capability to manifest itself in any part of the brain depending on how fast and far it 
grows.  In contrast, epilepsy is define as the tendency to have recurring unprovoked 
seizures (Engel, 2008) 
Over the years, many researchers have attempted to describe this disorder.  The 
International League Against Epilepsy (ILAE) successfully improved these descriptions 
(Trinka et al., 2015).  The ILAE provided the most impactful definition of epilepsy for this 
research: “A brain disorder characterized by an enduring predisposition to generate 
epileptic seizures and by the neurobiological, cognitive, psychological, and social 
consequences of this condition” (Fisher et al., 2005, p. 471).   
Epilepsy onset occurs with a bimodal lifetime distribution having two distinct 
modes.  The first peak is encountered during the initial two decades of life (epilepsy which 
is secondary to genetic and congenital aetiologies), whereas the second peak typically 
arrives over 60 years of age, resulting in late seizures after a stroke or tumour (Hauser, 
Annegers, & Kurland, 1993). The prevalence of active epilepsy is 0.5–1%.  It is also 
estimated that 2–5% of the population above the age of 70 will experience an epileptic 
seizure once in their lifetime (Behr, Goltzene, Kosmalski, Hirsch, & Ryvlin, 2016).  The 
rate of epilepsy’s growth is slightly higher in men than in women  (Thurman et al., 2011). It 
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is essential to evaluate the impact of this disease if confronted during the early years of life 
because the earlier that doctors treat this disorder, the better the outcome for the patient 
(García-Peñas, Fournier-Del Castillo, & Domínguez-Carral, 2014). Therefore, epilepsy is a 
condition considered as a worldwide health problem, which justifies the development of 
more research to explore interventions and to improve the comorbidities of patients that 
suffer from epilepsy. 
 
Epilepsy and Seizure Classification 
It is important to classify seizures to get a better understanding of their localisation 
and focal distribution and to provide a basis for prognosis providing the best possible 
treatment for the patient.  The ILAE has been trying for years to create a simpler and more 
comprehensible classification since previous classifications were more confusing and less 
accurate (Fisher et al., 2017).  The most recent classification in 2015–2016 was based on 
more scientific and clinical knowledge.  The first objective was to classify the initial 
manifestation of the seizure, which can be focal or generalized.  The symptoms presented 
during the seizure are then classified as motor or non-motor (sensory, cognitive, emotional 
or autonomic).  Finally, the classification considers the state of awareness.  The ILAE 
defined a focal seizure as “originated within networks limited to one hemisphere and 
discretely localized or more widely distributed; maybe originated in subcortical structures,” 
and a generalized seizure as “originated at some point within, and rapidly engaging, 
bilaterally distributed networks” (Berg et al., 2010).  A third group of seizures contains 
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those of an unknown onset with motor and non-motor symptomatology.  Figure 1 shows 
the most updated ILAE seizure classification differentiating each category.   
 
 
Figure 1. International League Against Epilepsy seizure classification 2017, Epilepsy Foundation 
<http://www.epilepsy.com/article/2017/12/2017-revised-clasiffication-seizures> 
 
Shorvon et al. (2011) proposed an etiological classification of epilepsy, as it is 
crucial for determining treatment and prognosis.  The classification includes four 
categories: idiopathic, symptomatic, provoked and cryptogenic.  Each category and 
subcategory with examples of pathologies that follow from them are described in Figure 2.   
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Figure 1. Etiological classification of epilepsy   
 
To better understand the types of seizures and their complexity, it is important to 
mention that this research was concerned with focal epilepsy.  The background research in 
neurofeedback has emphasized focal epilepsy. In addition, in generalized epilepsy there are 
is several neurophysiological components that are difficult to control and measure with the 
evaluating tools used in this study.  
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Epilepsy Mechanisms 
For a better understanding of the underlying mechanisms in epilepsy, it is important 
to consider the basic anatomy and neurophysiology of the cerebral cortex.  The human 
cerebral cortex consists of six neuronal layers.  The hippocampus, which is the oldest part 
of the cortex, is one region consisting of three layers, (Shipp et al., 2007).  It is localized in 
the temporal lobe and considered an important structure in the pathophysiology of epilepsy, 
as this is the region common for dysplasia, which is the malformation of the cortical 
development (Schwartzkroin, 1994).  The types of neurons in the cortex are differentiated 
by pyramidal neurons, most of which are a part of excitatory synapses; and interneurons, 
which have inhibitory synapses.  Recurrent inhibition forms synapses on inhibitory neurons 
and creates a negative feedback loop, which decreases function and stabilizes their 
function.   
The neurons are activated by an action potential that occurs due to the 
depolarization of the neuronal membrane.  This is an all or none activity due to the 
diffusion of ions through the membrane (Barnett & Larkman, 2007).  A hyperexcitable 
state occurs when there is an increase in excitatory synaptic activity, decrease in inhibitory 
activity, and change of the voltage-gated ion channels.  Figure 3 shows the relationship 
between the modification of the voltage of the membrane and the influx of ions  (Carlson, 
1992).  In epilepsy, it is crucial to understand this mechanism, as the influx of ions in the 
stabilization of the membrane is significant for proper functioning.   
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Figure 2. An action potential with the flow of ions (Carlson, 1992). 
 
Another important component in the mechanism of epilepsy is the role of the 
neurotransmitter, the chemicals released at the presynaptic level and activated by a 
postsynaptic receptor.  The main neurotransmitters are glutamate, gamma-amino-butyric 
acid (GABA), acetylcholine, norepinephrine, dopamine, serotonin and histamine.  The most 
important excitatory neurotransmitter is glutamate and its postsynaptic receptors, such as 
alpha-amino-2,3-dihydro-5-methyl-3-oxo-4-isoxazolepropanoic acid (AMPA), kainite 
receptors and alpha N-methyl-D-aspartate (NMDA), which are responsible for an adequate 
ion influx; agonism of these receptors can induce seizure activity (Pincus, 1992). 
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The inhibitory neurotransmitter GABA relates with two receptors: GABA-a and 
GABA-b.  GABA-a receptors are permeable to chloride (Cl-), which hyperpolarizes the 
membrane and inhibit action potentials; whereas substances that are GABA-a agonist 
suppress seizure activity.  GABA-b relates to the second messenger system and often 
results in the opening of potassium (K+) channels causing a hyperpolarization; GABA-b 
agonist exacerbates hyperexcitability and seizures (Treiman, 2001).   
The electrical activity of the brain takes place in two environments: within the 
neuron (intrinsic) or in the extracellular space (extrinsic).  The intrinsic mechanisms depend 
on the  type, number and distribution of ligand-gated channels as these channels determine 
the directions, degree and rate of changes in  the transmembrane potential and the extrinsic 
mechanism depends on extracellular ion concentrations as it varies the extracellular volume  
(Bromfield, Cavazos, & Sirven, 2006).   
There are various factors underlying the pathophysiology of epileptogenesis that 
disrupt the imbalance of the excitation and inhibition of the neuronal activity, disturb 
extracellular ion homeostasis alter energy metabolism, change receptor functions and 
change transmitter uptake (Le Magueresse et al., 2013).  There are major mechanisms of 
hyperexcitability of the neural network that are not exclusive, as between them they 
synergize in epilepsy: (a) selective loss of interneurons, (b) selective reorganization that 
creates recurrent excitatory connections and (c) loss of excitatory neurons that stimulate 
inhibitory neurons (Benini & Avoli, 2005).   
Kindling is a phenomenon that explains epileptogenesis such as alterations within 
the glutamate channel, selective neuronal loss and axonal reorganization (Corcoran, 1989).  
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However, we still do not know of all the mechanisms that occur.  Rather, we understand 
that continuous electrical chemical activation of a specific area of the brain involves long-
lasting biochemical or structural changes that affect the central nervous system (CNS) 
(Bertram, 2007).   
Epilepsy and Comorbidities 
In contrast to recurrent seizures, epilepsy is usually diagnosed alongside other 
cognitive and behavioral issues that are more disabling than the seizures.  Amongst 
epileptics, quality of life (QOL) is affected more by factors such as social life, family life, 
academic achievement, and professional achievement, than by seizures (Keezer, Sisodiya, 
& Sander, 2016).  
Neurobehavioral comorbidities in epilepsy.  Population-based and community-
based studies documented the prevalence of neurobehavioral comorbidities in epilepsy, 
which are divided into psychiatric, cognitive, and social categories (Lin, Mula, & Hermann, 
2012).  Severe epileptic encephalopathy, which commences in early childhood, more 
frequently has complex comorbidities.  According to the ILAE, “The epileptic activity itself 
may contribute to severe cognitive and behavioural impairment above and beyond the 
expected from the underlying pathology alone” (Berg et al., 2010).  Roughly 75% of 
children diagnosed with epilepsy are affected with epileptic syndrome (Lennox-Gastaut, 
West, & Dravet).  This syndrome gives rise to encephalopathy that may result in mental 
retardation and/or autism (Berg, 2011) 
Psychiatric comorbidities.  Various researchers, such as García-Peñas et al. (2014) 
and Aaberg et al. (2016), have documented that patients suffering from epilepsy may also 
EPILEPSY AND NEUROFEEDBACK  29 
have mood disorders, anxiety disorders, and attention deficit hyperactive disorder (ADHD), 
as well as other psychiatric disorders (Aaberg et al., 2016).  Tellez-Zenteno, Patten, Jette, 
Williams, and Wiebe (2007) found that patients who have experienced early presentation of 
epilepsy suffer from more evident comorbidities than people diagnosed later in life.  These 
disorders also are associated with non-complicated epilepsy, though they are more common 
with complicated epilepsy (Tellez-Zenteno et al., 2007).   
In a population-based study in England, Rai et al. (2012) found that one third of 
people with epilepsy met diagnostic criteria for anxiety and depressive disorders, compared 
with one in six in the general population without epilepsy. Kessler, Lane, Shahly, and Stang 
(2012) showed that the association of epilepsy with days of role impairment due to 
comorbidities is equivalent to 89.4 million days off annually among U.S. adults with 
epilepsy, which is significantly higher than among a healthy population.   
Cognitive comorbidities.  In a review of the literature concerning neurobehavioral 
comorbidities in the community-based investigation of paediatric epilepsy, Lin et al. (2012) 
found increased cognitive dysfunction in children with epilepsy, including uncomplicated 
epilepsy, when compared with healthy children.  Table 3 presents the literature discussed in 
this review. 
EPILEPSY AND NEUROFEEDBACK  30 
Table 1  
Cognitive Comorbidities in Paediatric Epilepsy Population-Based Studies 
Ellenberg, Hirtz, and 
Nelson, (1986) 
IQ <70 in 27% of children with epilepsy (Ellenberg et al., 1986) 
Berg et al. (2008) Impaired non-verbal intelligence in 47% of children with 
epilepsy compared with 3% of healthy control individuals 
 Impaired executive function on seven of eight tests in children 
with epilepsy compared with healthy control individuals  
 IQ <80 in 25% of children with epilepsy (Berg et al., 2008) 
Fastenau et al. 
(2009) 
Children with epilepsy did worse than healthy control 
individuals on four of four cognitive domains (Fastenau et al., 
2009) 
Jones, Siddarth, 
Gurbani, Shields, W. 
and Caplan, R. 
(2010) 
Children with epilepsy (uncomplicated) has lower verbal IQ, and 
learning than did healthy control individuals (Jones et al., 2010)   
  
Other authors have shown that at least a quarter of all children diagnosed with 
epilepsy experience cognitive difficulties (Berg et al., 2008).  Epileptic activity may restrict 
proper functioning and development of the brain by preventing adequate function of 
cortical networks (Berg et al., 2011).  The age of onset and the number of seizures are two 
factors that associate positively with the extent of cognitive dysfunction (Vasconcellos et 
al., 2008) 
Berg et al. (2011) examined the factors that may impact other functions in an 
epileptic patent, such as structural defects and the consequences of abnormal cognitive 
processes. One of the most common structural defects observed in children was deformity 
in the development of the cerebral cortex region of the brain (Berg & Scheffer, 2011) .  
Such structural abnormalities hinder the proper functioning of the brain and result in 
several cognitive impairments.  This disruption in intellectual and cognitive behavior is due 
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to the transient effects of seizures that last for a long period of time (Kim et al., 2016). 
Additionally, patients with mesial temporal lobe epilepsy (MTLE) experience progressive 
drops in cognitive function, an advanced effect of epilepsy.  This leads to the thinning of 
the neocortex, which can degenerate memory in a span of four years (Hermann et al., 2006) 
Taylor et al. (2010) further documented comorbidities among patients recently 
diagnosed with an epileptic disorder prior to starting antiepileptic drugs (AED) and 
compared those to a healthy population.  The authors suggested that the cerebral 
deficiencies present in the patients preceded the commencement of epilepsy as the scores 
were expressively low in all cognitive areas.  The patients tested with fewer seizures 
experienced the same effects, indicating that AED were not the primary source of their 
deterioration (Taylor et al., 2010) 
Social comorbidities.  The social aspects of epilepsy are important factors that 
affect the QOL of patients with epilepsy.  Discrimination within society can often be more 
challenging than the disease itself (Viteva & Semerdjieva, 2015).  In many countries, the 
laws reflect a lack of understanding of the social dimension of epilepsy.  For example, 
epilepsy in China and India is generally regarded as a reason to forbid or terminate a 
marriage.  Until 1970, the law in the United Kingdom prohibited people with epilepsy from 
marrying (Kilinç & Campbell, 2009).  In the United States, until 1970, individuals with 
epilepsy were denied access to restaurants, theatres, and recreation centres. The stigma of 
this disorder may affect patients who seek treatment, as they may feel ashamed to ask for 
help (Pan, Gupta, Wyllie, Lüders, & Bingaman, 2004) 
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As a medical diagnosis, epilepsy may serve as a stigmatizing social label (Jacoby, 
Johnson, & Chadwick, 2015). In previous eras, people with epilepsy have been viewed as 
possessed by demons, infectious, or insane, leading individuals to hide their condition 
socially (Sleeth, Drake, Labiner, & Chong, 2016).  Patients experiencing social non-
acceptance may develop anxiety, low self-esteem, hostility, and maladaptive behaviors 
(e.g., dependency, rigidity, anger, and aggression) that affect their QOL (Livneh & 
Antonak, 2005). 
Economically, epilepsy treatments are quite costly.  Substantial funds are required 
to pay for medication, treatment procedures, lack of productivity, and premature death.  
People with epilepsy face financial crises, and often have limited access to health services 
and insurance.  These individuals have no chance of obtaining a driver’s license and may 
face difficulty securing employment.  As such, the ideal treatment for epilepsy disorder 
includes proper psychological, financial and social support (Stefan et al., 2014) 
Early diagnosis and treatment is essential as the most significant 
neurodevelopmental changes occur during childhood and adolescence.  These changes 
impact patients’ lives academically, emotionally, and economically.  Early diagnosis and 
intervention may reverse some cognitive injuries.  For example, patients may recover their 
development quotient through successful surgical treatment (Freitag & Tuxhorn, 2005; 
Jonas et al., 2004). 
Psychological comorbidities.  The factors responsible for the psychological 
influence of epilepsy on the child and family’s everyday life suggested by Camfield, Breau, 
and Camfield (2001) include: (a) the discipline of the brain disorder, (b) the availability of 
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the medical administration, (c) the significance of the disease to the child and family 
socially, (d) boundaries on the family’s events, (e) difficulty and innate coping mechanisms 
and (f) the extent of assets and social livelihood available to deal with epilepsy (Camfield et 
al., 2001).  The difficulty of the situation stems from the fact that the arrival of sporadic and 
unpredictable conditions resulting from epilepsy can cause mental distress to parents.  The 
difficulty of the situation can affect the child’s confidence  (Rodenburg, Wagner, Austin, 
Kerr, & Dunn, 2011). It can also affect parenting duties and create family difficulties.  
Thornton et al. (2008) observed that children with poor control and prognosis pose 
obstacles that affect family dynamics.  Additionally, children diagnosed with epilepsy 
experience lower self-esteem that affects their relationships with friend and relatives 
(Sturniolo & Galletti, 1994) 
Quality of Life and Epilepsy 
Epilepsy negatively impacts the QOL of a patient (Lai et al., 2015).  If the condition 
begins during childhood, the patient may develop a dependent personality with severe 
disabilities that impact social development and the ability to live independently.  It is often 
difficult for people outside of the environment of epilepsy to understand how this disorder 
may lead to disabilities, as the patient may look normal and not present all related issues in 
public settings. 
Vickery et al. measured quality of life in research to evaluate the efficacy of 
medical, surgical, and rehabilitative interventions, to provide an indicator of quality of care, 
health care and health behavior, comparison of impairments across the disease and 
evaluation of the cost-benefit ratio (Vickrey, 1993).  While QOL generally includes life 
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satisfaction, self-esteem, well-being, health, and happiness (Frank-Stromborg, 1988), QOL 
is the state of overall health that includes the domains of physical, social, psychological, 
vocational and economic well-being (Spencer & Hunt, 1996) 
Hosseini, Mokhtari, Momeni, Vossoughi, and Barekatian (2016) reviewed extensive 
literature on the QOL for patients suffering from epilepsy.  Epilepsy affects mortality and 
distresses patients socially, psychologically, and cognitively.  People suffering from 
epilepsy are uncertain about their life expectancy, and this affects their QOL significantly.  
Patients with epilepsy cannot predict when, where, and in which circumstance their seizures 
will erupt (Murray, 1993).  In addition, patients may not know how each seizure will affect 
them, or if it will have damaging effects on their functioning.  As such, once patients are 
diagnosed with epilepsy, they must learn to cope with the repercussions of seizures.  They 
should be aware of the treatment required for them in these circumstances.  Yet seeking 
psychological and emotional support may be challenging for the patients (Taylor, 1989).   
Kwong et al. (2015) found that adolescents with epilepsy demonstrate higher rates 
of anxiety and depression when compared with adolescents who suffer from asthma (38.2% 
anxiety and 22.2% depression).  The authors also found that polytherapy and older age 
were correlated with higher anxiety level.  The results showed that key factors associated 
with depression among females were high seizure frequency and early age of onset (Kwong 
et al., 2015).  The authors also found that the duration of epilepsy is another common 
component in both anxiety and depression.   
EPILEPSY AND NEUROFEEDBACK  35 
Collings (1990) examined the impact of epilepsy on patients’ well-being as well as 
social/family circumstances.  The authors aimed to improve the evaluation and 
measurement of QOL among epileptic patients (Collings, 1990). 
There are sufficient QOL scales to evaluate the outcome of treatments and 
interventions for epilepsy.  For clinical use, generic scales have been developed to measure 
general health conditions. However, for epilepsy, the specific issues that affect certain areas 
of life are neglect in generic scales.  Thus, disease-specific scales measure distinct aspects 
of this disease (Cowan & Baker, 2004).   
Epilepsy and Therapeutic Interventions 
It is important to understand the current therapeutic options available for patients 
with epilepsy in order to treat the condition adequately.  This section, describes the various 
therapeutic interventions (Table 2), as well as the need for improved therapies for epilepsy.   
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Table 2 
Available Therapeutic Interventions for Epilepsy, Efficacy and Negative Points 
 Intervention Efficacy Negative points 
Conventional Antiepileptic 
drugs 
70%  Cognitive decline 
Behavioural issues 
Systemic symptoms (renal, 
hepatic) 
Overmedication 
Addiction 
Surgery 56% Invasive surgery 
Complications of surgery 
Expensive 
Cognitive issues 
Seizures relapse 
Neuromodulation Vagus nerve 
stimulation 
57% Invasive procedure 
Complications of surgery 
Deep brain 
stimulation 
56% Invasive procedure 
Complications of surgery 
Trigeminal 
nerve 
stimulation 
40% Not enough evidence  
Transcranial 
direct current 
stimulation 
58% Not enough evidence 
Repetitive 
transcranial 
magnetic 
stimulation 
50% Expensive  
Low availability 
Others Ketogenic diet Unknown Not possible to follow for long 
periods of time 
Acupuncture Unknown Not enough evidence 
 
Antiepileptic drugs (AEDs).  These drugs are used as a conventional treatment for 
epilepsy, and have a 70% success rate among newly diagnosed children and adults 
(Dwivedi, Singh, Kaleekal, Gupta, & Tripathi, 2015).  However, it is a frequent practice to 
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overmedicate patients even if there is not much clinical improvement after the treatment is 
provided (Chuang et al., 2007).  The risk and benefits of AED should be monitored 
continuously to control the frequency of seizure.  In addition, it is also important to 
consider if the treatment is able to optimize cognitive, psychological and social functioning 
(Jovanovic, Jocic-Jakubi, & Stevanovic, 2015).   
Side effects of AED are abundant and should be evaluated with respect to the 
treatment required for the patient.  Approximately 90% of patients suffering from epilepsy 
experience an unwanted side effect of AED (Thomas, Koshy, Nair, & Sarma, 2005).  
Neurotransmitter systems, neuronal ion permeability, and other targets, are affected by 
AED.  However, the precise mechanisms affected by AED are not fully understood because 
they are so complex.  After undertaking a systematic review of the literature by (Piedad, 
Rickards, Besag, and Cavanna (2012), evidence of unfavourable effects of epilepsy 
documented including depression, anxiety, aggression, psychosis and sleep disorders. Thus, 
there is a need to look for alternative therapeutic options for epilepsy.   
Surgery.  Surgical options include resection of a brain lobe or specific brain 
structures such as temporal lobectomy, lesionectomy, hemispherectomy, and corpus 
colostomy.  However, surgery is not always an effective treatment (Najm et al., 2013).  The 
failure of the surgery could lead to adequate trials of seizures due to side-effects of AED 
(Asadi-Pooya et al., 2014).  In the last decade, approximately 5% of the paediatric epilepsy 
population were candidates for surgery (Sugano & Arai, 2015).  Typically, the patients who 
suffer from malformation of cortical development are better candidates for surgery.  In 56% 
of cases, surgery is successful, defined as seizure free at 3 months follow up (Mühlebner et 
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al., 2014).  The use of highly invasive techniques may severely affect neuropsychological 
functions and impede memory.  Additionally, after five to ten years of surgery, in general, 
50–60% of patients report experiencing seizures again (Kwan & Sperling, 2009) 
It is also important to consider constraints associated with the monetary cost and the 
availability of the surgical option for such patients.  In developing countries, over 40 
million people suffer from epilepsy and access to accurate imaging studies, 
electrophysiology, metabolic testing, and state-of-the art surgical equipment to perform 
surgery successfully may be limited (Asadi-Pooya et al., 2014). 
Vagus nerve stimulation (VNS).  This treatment is a nonpharmacological, 
moderate-risk surgical intervention option that aids epilepsy treatment.  It is used for 
patients suffering from refractory epilepsy.  It has a success rate of 57% (Rocha, 2013).  
The procedure consists of an implantation of a programmable signal generator in the chest 
cavity and an electrode that produces electrical stimulation over the vagus nerve (Schachter 
& Saper, 1998).  One of the mechanisms of action is an increase of parasympathetic tone to 
reduce the cortical hyperexcitability and reduce seizures (Bodin et al., 2015).   
Deep brain stimulation (DBS). This treatment uses intracerebral implantation to 
stimulate electrodes.  The electrodes are connected to a subcutaneous pulse generator, and a 
pulse of electrical current is continuously delivered to the parts of the brain to be 
modulated.  In epilepsy, anterior nucleus (AN) and centromedian nucleus of the thalamus 
are frequently stimulated.  Kocabicak, Temel, Höllig, Falkenburger, and Tan (2015) found 
that 56% of patients reported a reduction in seizures after this treatment.  However, DBS is 
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another invasive intervention and its risks and side effects must thus be evaluated (Halpern, 
Samadani, Litt, Jaggi, & Baltuch, 2008). 
Trigeminal nerve stimulation (TNS).  This is a non-invasive technique that uses 
neuromodulation principles.  The mechanism is based on reducing cortical spiking and 
prolonging the refractory period of cortical pyramid neurons. Soss et al. (2015) studied this 
intervention in epilepsy and showed reduced cerebral blood flow and metabolism in the 
sensorimotor cortex, parietal cortex, and temporal cortex in images. In addition, positive 
response rates of 42% and 40.5% respectively have been observed in two clinical trials. 
Thereafter, a response rate of more than 30% reported after a six to twelve-month follow-
up with those exposed to the intervention (Soss et al., 2015). 
Transcranial direct current stimulation (TDCS). This treatment modulates 
cortical excitability via a non-invasive brain stimulation technique.  A weak and constant 
electric current passes through two electrodes (anode and cathode) on the scalp.  The 
cathode stimulation reduces cortical excitability, whereas the anodal stimulation increases 
it.  The hyperpolarization occurrence is used in epilepsy for stimulation.  In a recent 
systematic review, San-Juan et al. (2015) concluded that TDCS trials showcased 
preliminary safety and efficacy among animals and epileptic patients.  The authors also 
found that there were benefits of this intervention over other neuromodulation therapies as 
well, as TDCS uses less expensive and compact equipment.   
Repetitive transcraneal magnetic stimulation (rTMS).  This treatment aims to 
modulate cortical excitability.  In rTMS, a magnetic current is applied to the surface of the 
scalp, which targets specific parts of the brain.  Some clinical trials have shown that 
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stimulating the epilepsy foci produce a 50% success rate from rTMS treatment (Lefaucheur 
et al., 2014).  However, rTMS requires costly equipment. 
Ketogenic diet.  Refractory epilepsy treated with a dietary option known as the 
ketogenic diet.  In this diet, high amounts of fats, adequate quantities of protein, and low 
carbohydrates are consumed by patients.  In refractory epilepsy, the body consumes more 
fat than carbohydrates.  Thus, it requires the number of ketones to be increased in the 
bloodstream.  The brain uses the ketones instead of glucose, and this mechanism helps in 
reducing seizure activity (Freeman, Kossoff, & Hartman, 2007).   
Acupuncture.  An alternative therapy to treat neurological disorders is acupuncture, 
a conventional Chinese form of therapy (Zhao, Rong, & Zhu, 2015).  It is a safe and non-
invasive intervention.  Acupuncture stimulates the thalamus as it is the sensory brain 
regulator and connected with epilepsy genesis. Chen et al. (2014) showed that this 
intervention is associated with neuromodulatory techniques and can offer advantages to 
patients who suffer from refractory epilepsy. 
Based on the information provided of the current therapeutic intervention for 
epilepsy, there is evidence that there are still clinical issues that are not fully resolved.  In 
order to improve epilepsy and the comorbidities, there is need to explore less invasive 
treatments with fewer side effects and cost-effective interventions. 
 
Conclusion 
This chapter showed the general characteristics of epilepsy and the complexity of 
clinical presentation, as well as how limited, risky, costly, and severe the available 
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therapeutic interventions can be.  These reasons justify an exploration of additional 
interventions that treat seizures and comorbidities as well as offer lower risk approaches 
that reduce side effects for this population.   
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Chapter 3    Introduction to Electroencephalogram 
An electroencephalogram (EEG) is a recording of brain activity taken from scalp 
electrodes.  The modernisation of the technology has led to its extensive use.  Berger first 
studied EEG signals in 1929 (Jung & Berger, 1979) and since then neurological and 
psychiatric disorders, such as epilepsy, stroke, head injury, brain tumour, and sleep 
disorders, are diagnosed using EEG signals.  The recorded activity results from action 
potentials that arise out of cortical neurons, which produce EEG rhythms.  Excitatory and 
inhibitory postsynaptic potentials (EPSPs and IPSPs) are then stimulated and further 
produce pyramidal cells in the cortex.  Subcortical structures such as the thalamus play an 
important role in understanding the origins of EEG rhythms (Mitzdorf, 1987).   
The oscillations produced by the thalamo-cortical circuits instigate the firing of 
layer IV cortical neurons, and a dipole of negativity and positivity are created on the 
superficial layers of cortex.  The electrodes produce fluctuations after reading these 
changes in potentials.  The electrical activity measures the voltage differential between the 
two electrodes since the electrical activity needs to travel from one point to another point.  
Complex information processes can be measured by the EEG via the neural system in the 
central nervous system and the peripheral neural system (PNS) (Tyner, Knott, & Mayer, 
1989).   
For clinical practice, 20 electrodes are placed on the scalp in a specific localization 
in a 10/20 system (see Figure 4) (Knott, 1993).  This is an international and standardized 
method to describe the localization of the electrodes on the scalp and is based on the 
relationship between location of an electrode and the underlying area of the cerebral cortex, 
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and electrode can record activity from 6 cm2 of cortex.  Frequency indicates how fast the 
waves oscillate, which is measured by the number of waves per second (Hz), while 
amplitude represents the power of these waves measured by microvolt (µV).  High density 
EEGs with 123 additional electrodes provide high source location accuracy in epileptic 
patients (Meckes-Ferber, Roten, Kilpatrick, & O’Brien, 2004). 
 
Figure 3. 10/20 system of electroencephalography electrode placement. 
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Electroencephalogram has developed from paper documentation to computer-based 
data analysis, display and storage.  An analogue-digital converter (ADC) device can be 
used to convert the analogue EEG signal to digital values and save it in digital media, such 
as on hard discs or compact discs (Nuwer et al., 1998). 
The Signal Processing of the EEG 
The EEG signal has linear properties.  For example, the activity between 10–300 
μV can be easily assessed with physiological and electrical noises and artefacts from 
electrocardiogram (ECG), electrooculogram (EOC) and electromyogram (EMG).  
Electroencephalogram is not a static process that relies on a physiological state.  There are 
non-physiological artefacts that can contaminate the EEG, such as the 50/60 Hz artefact.  
Electrical devices such as TV stations, radio, pagers, telephones, or a cardiac pacemaker, 
can produce these artefacts.  However, these artefacts can be easily eliminated using a 
notch filter and eliminated from analysis (Barlow, 1993).  The EOG and ECG are the most 
challenging artefacts to remove because they overlap with the EEG amplitude. 
The clinical application of EEG includes the diagnosis of seizure disorders, sleep 
disorders, altered levels of consciousness, infections and affective and behavioural 
disorders (Kupfer, Reynolds, Ulrich, Shaw, & Coble, 1982).  Different frequency bands can 
be recognized in the EEG that relate to levels of alertness: delta (0–3+ Hz), theta (4–7+ 
Hz), alpha (8–13+ Hz), and beta (>14 Hz).  Table 3 shows the EEG characteristics of each 
band (Niedermeyer, 1998).  The posterior dominant rhythm (8–13 Hz in adults) is observed 
within the posterior head region, and the amplitude can be altered by having the eyes closed 
or open (see Figure 4).  The activity can be synchronized and symmetrically organized via 
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an intrinsic pacemaker through the thalamus.  Any abnormalities in the thalamic pacemaker 
indicates an irregularity in the central nervous system (Papazian, 1990).   
Table 3  
EEG Frequencies and Related Brain Activity 
Frequency Band Frequency Range (Hz) Brain Activity 
Delta 1-4 Sleep, unawareness, deep-
unconsciousness 
Theta 4-8 Unconsciousness, optima 
meditative state, 
distractibility.   
Alpha 8-13 Alertness, deeply relax, 
recalling, optimal cognitive 
performance.   
SMR 12-15 Mental alertness, physical 
relaxation 
Beta 15-32 Focusing, sustained 
attention, alertness, 
excitement. 
Gamma 32-40 Cognitive processing 
 
 
Figure 4. Normal adult electroencephalography with reactive activity during eyes closed (personal clinic 
data).
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EEG Profiles Associated with Epilepsy 
The most common abnormality in a localized brain lesion is abnormally slow focal 
activity.  If generalized slowing is noted, then the output is considered to be consistent with 
encephalopathy.  Transient abnormalities are indicated by spikes, sharp waves, spike and 
slow waves complexes, which can be focal or generalized (Koren et al., 2016).  Figures 5 
and 6 show the typical EEG profiles for focal or generalized seizures respectively.   
 
Figure 5. EEG profile for focal epilepsy.  Left anterior temporal spike (personal clinical data). 
 
Figure 6. EEG profile spike and slow wave, generalized epilepsy (personal clinic data). 
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The neurophysiological mechanism of a focal seizure begins with a high amplitude, 
a recurring burst of activity, and hypersynchrony of a neuronal populations.  If an 
appropriate number of neurons synchronise in a burst, it results in a spike discharge on the 
EEG (Perucca, Dubeau, & Gotman, 2014).  A mechanism called paroxysmal depolarization 
shift is associated with the influx on Ca++ extracellular, which is related to an opening of 
Na+ channels and produces a repetitive action potential.  Subsequently, hyperpolarization is 
associated with the GABA receptors and the presence and quantity of Cl- or K+ ions.  The 
propagation of the seizure occurs when there are enough neurons in surrounding areas that 
the central area is activated and producing a surrounding inhibition that spreads the seizure 
activity over cortical pathway (Kandel & Buzsáki, 1993).  Once repetitive discharges 
happen, there is an increase of extracellular K+ ions and depolarized surrounding neurons.  
The build-up of Ca++ in presynaptic regions produces neurotransmitter turns and the 
depolarization of NMDA, which causes additional Ca++ and more neuronal activation 
(Eross et al., 2009).   
Quantitative Electroencephalogram (QEEG) 
The American Academy of Neurology defined the QEEG as “the mathematical 
processing of digitally recorded EEG in order to highlight specific waveforms components, 
transform the EEG in to a format or domain that elucidated relevant information, or 
associate numerical results with the EEG data for subsequent review or comparisons” 
(Nuwer, 1997).  Novel techniques have been implemented to comprehensively assess brain 
function and connectivity. Linear and nonlinear methods as theory-based time series were 
implement. Fast Fourier transformation (FFT) has been one of the theorems used for this 
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purpose (see Appendix A for QEEG analysis methods). Fast Fourier transformation 
provides numeric values decomposing the waves into voltage of each frequency which 
provide power spectrum data driven from a QEEG analysis are the following: spectral 
analysis (frequency composition over given time); absolute power (power is the square of 
the EEG amplitude, mathematically it indicates the strength of the signal at the given 
frequencies interval); and coherence (analogous to cross-correlation in the frequency 
domain between activity in two channels) (Grin-Yatsenko, Baas, Ponomarev, & Kropotov, 
2010). 
High levels of split-half and test-retest reliability for the QEEG, as well as 
predictive validity, were demonstrated in a review of the literature by Hughes and John 
(2014).  A QEEG greater than 0.9 correlation is considered reliable and has 40s seconds 
epoch.  Predictive validity of QEEG was established by implementing replicable 
correlations that comprised of clinical measures and provided accurate predictions of the 
outcome and performance of neuropsychological tests.  Content validity of QEEG 
established by constructing correlations with independent measures such as magnetic 
resonance imaging (MRI), positron emission tomography (PET) and single photon 
emission computed tomography (SPECT), the Glasgow Coma Score (GCS), and other 
neuropsychological tests.  Thatcher Biver, and North (2003) found substantial correlations 
between the QEEG and independent measures, which related to attention deficit disorder, 
depression, and anxiety.   
The innovations of the present study are the combination of clinical, neurological 
and psychological measures.  Previous neurofeedback studies with epilepsy focused on 
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specific variables, such as seizure frequency, and did not examine the effects of 
intervention in young people who suffer from epilepsy 
The main objective of using the QEEG as a neurological outcome for a 
neurofeedback study is to provide objective information about brain activity (absolute 
power and coherence) that can be compare over time.  This objective data is not measurable 
in a conventional EEG as we only rely on visual analysis.  In epilepsy, the use of QEEG 
can be valuable as seizure disorders are not localized anomalies in the cerebral cortex but 
rather dysfunctions within and between networks in cortical and subcortical structures 
(Pittau & Vulliemoz, 2015).   
Walker (2008) found that 75% of patients suffering from intractable epilepsy 
witnessed proliferation in theta absolute power, in addition to a 50% rise in coherence 
within theta and beta bands.  The author concluded that by lowering the absolute power of 
Theta and by decreasing the Theta and Beta coherences, seizures could be controlled more 
effectively.  Birca et al. (2015) demonstrated that children with febrile seizures experience 
heightened Theta coherence in seizure prone state, which interferes with the process of 
brain maturation and in the development of interconnectivities in the brain.  Kober et al. 
(2015) also demonstrated that healthy adults could voluntarily proliferate production of 
SMR absolute power and simultaneously reduce the Beta coherence.  Sterman (1996) 
suggested that the reduction in coherence is an indication of reduced mutual interference 
which can perhaps boost stimulus processing.  Thus, in this study, Theta and Beta 
coherences were analyzed. 
 
EPILEPSY AND NEUROFEEDBACK  50 
Conclusion 
This chapter covered the background of the EEG and QEEG as neurofeedback is an 
intervention based on EEG signal, but also because the study includes neurophysiological 
outcome measures, so it is important to have the background for the purpose of the study.  
Also, there is more clear understanding of the rational of the variables used in this 
study to measure neurophysiological outcome.  
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Chapter 4    Neurofeedback Background 
Neurofeedback, also known as a brain biofeedback, brain-computer interface (BCI), 
or brain-machine interfaces (BMI), is an intervention whereby the activity of the neuronal 
process is registered and regulated.  Neuronal activity is measured and, in real-time, visual 
and auditory feedback is presented to self-regulate the electrical activity of specific brain 
structures that are related to a specific behavior and symptoms.  As the patient is exposed to 
the intervention in repetitive sessions, different learning mechanisms are activated for the 
modification of the behaviors.  For this reason, neurofeedback can be considered as  
endogenous neural stimulation (Shibata, Watanabe, Sasaki, & Kawato, 2011). Figure 8 
illustrates the visual and auditory feedback compared with other neuroimaging methods and 
the feedback calculations.  
 
Figure 7. Overview of the procedure of neurofeedback. Adapted from Sitaram et al. (2016).  
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Neurofeedback begins with the observation of neural activity.  Electrophysiological 
methods to detect such activity include electroencephalography (EEG), 
magnetoencephalography (MEG), and invasive electrocorticography (ECoG).  Sample 
signals that are extracted from the sensor channels provide a qualitative representation of 
the difference in temporal resolution.  Univariate approaches extract a signal from a single 
channel or region of interest as, for example, an evoked potential.  Calculation of coherence 
or connectivity between two channels as a measure of functional connectivity is another 
common feedback method.  Features from a set of sensors, such as the power at a frequency 
window or the level of activation, can be classified as multivariate patterns of activity 
(MVPAs).  The calculated signal is then presented to the individual via visual and auditory 
feedback, allowing the user to alter neural function and complete the loop with neural 
processing of feedback.  
Newer technology includes rt-fMRI (real time functional magnetic resonance 
imaging) neurofeedback, which showed to be accurate in modifying specific cortical 
activity of target brain regions. This  exciting neuroimaging technique is the type of 
neurofeedback that has been shown to be more effective in effecting positive outcome in 
different neurobehavioral conditions (Kopel et al., 2017). For epilepsy, there is not enough 
evidence for the use of this technique, and unfortunately, it is a costly intervention. For this 
reason, the present study included the neurofeedback modalities the showed efficacy in the 
treatment of epilepsy.  
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Learning Theories in Neurofeedback 
Neurofeedback emerged from learning theories, especially associative learning 
theory, which includes the notion of classical conditioning and operant conditioning 
(Strehl, 2014).  Classical conditioning is a type of learning that involves the acquisition of 
elicited responses, while operant conditioning is a type of learning that involves the 
acquisition of emitted responses (Kirsch, Lynn, Vigorito, & Miller, 2004).  In 1927, Pavlov 
conducted an experiment popularly known as classical conditioning, in which an 
unconditioned response (“inborn reflexes”) was generated as a result of an unconditioned 
stimulus (Pavlov, 1927).  In that experiment, Pavlov used a dog and measured the effect of 
saliva during digestion.  The meat powder was used as a stimulus for the dog while the 
saliva was the result of a conditioned stimulus.  Pavlov observed that the dogs salivated 
even before the meat power was presented in front of him.  The dog salivated as he heard 
the sound of the steps of the person who brought the meat powder or after listening to the 
noise produced by the device that delivered the meat powder.  The dog associated the ring 
of the bell to the deli of meat power and, after several rings, when the bell rang the dog 
produced saliva (Gantt, 1927) 
Through this experiment, Pavlov demonstrated that when stimulus and response are 
linked, they can become the basis of learning.  The meat powder was the unconditioned 
stimulus (UCS) and the dog’s salivation was the unconditioned response (UCR).  The 
ringing of the bell was an auditory stimulus and acted as a neutral stimulus until the dog 
was conditioned to salivate after listening to the ringing.  Thus, the bell became the 
conditioned stimulus (CS) that produced a conditioned response (CR).  Hence, a 
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physiological function does not always require a learning process (e.g., salivation at the 
sight of food) using classical conditioning.  In this process, the conditioned stimulus 
produces a conditioned response (e.g., saliva after hearing person’s footsteps who brings 
food for the dog) (Pavlov, 2010). 
Researchers working to understand better the mechanism of neurofeedback have 
explained how operant conditioning also implies a role in the intervention.  By proposing 
the “law of effect,” Thorndike and Skinner (1948) described operant conditioning on newly 
learned behaviors. Such behavior was not observed in Pavlov’s studies on classical 
conditioning.  Operant conditioning is based on a response that generates a substantial 
effect in a given situation.  Such an effect usually contrasts with expectations; the responses 
produced thereafter have discomforting effects and are less likely to happen again (Skinner, 
1960). The theory of operant conditioning thus increases the desired behavior and decreases 
the undesired behavior.   
Typically, undesired behavior is punished and desired behavior is rewarded.  A 
reward includes any situation in which the desired response is considers desirable and 
promotes an exact response under the same conditions.  A punishment is an action that is 
given when an undesired response is discouraged.  It prevents the occurrence of an 
undesirable event.  If the frequency of reward or punishment increases or decreases, then 
the response is reinforced (Bauer & Gharabaghi, 2015).  The reinforcement and punishment 
may be positive or negative.  Positive reinforcement means providing a stimulus, and 
negative reinforcement indicates the removal or absence of the stimulus.  Furthermore, 
extinction is induced by a lack of consequences following a particular behavior.   
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Neurofeedback learning involves an initial stage of fast change in performance and 
a late stage of more stable improvement as the skill is consolidate. VanLehn (1996) showed 
functional and structural changes in the dorsomedial striatum to be associated with the first 
stage, whereas such changes in the dorsolateral striatum are associated with the late stage. 
Brain Activity Conditioning 
Durup and Loomis (1935), Jasper and Shagass (1941) and Kamiya (1958) were 
pioneers in experimenting with human brain activity conditioning.  These experiments 
showed that the human brain can be trained to produce specific brain activity voluntarily 
paired with a specific stimulus, at this moment without knowing that this could lead to a 
clinical use for neurological disorders.   
Durup and Rouanet (1968) and Loomis et al. paired a low auditory tone with light 
stimulus that resulted in alpha blocking and extinction if the low tone was presented several 
times devoid of the light stimulus. Jasper and Shagass (1941) questioned whether alpha 
blocking was not simply an unconditional response to light, and demonstrated the voluntary 
control of EEG by associating with it a vocal stimulus. The authors instructed the 
participants voluntarily say sub-vocally ‘‘block’’ and press a button followed by a sub-
vocal ‘‘stop’’ and release of the button.  The button switched on the light, serving as the 
unconditioned response, associating the sub-vocal command with alpha blocking and hence 
becoming the conditioned response (Jasper & Shagass, 1941).  Later, Kamiya (1958) 
demonstrated that the human brain can voluntarily discriminate between high and low 
amplitudes of EEG alpha rhythms when a trainer gave a command (Kamiya, 2011). 
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Regardless the light or vocal stimulus, these studies showed that the human brain activity 
can modify their activity following learning theories. 
Sterman et al. (1969) conducted an animal experiment regarding classical 
conditioning of brain activity.  Using cats, the authors synchronized EEG activity and 
behavioral manifestation of sleep.  The cats were conditioned with a tone that rested in 
basal forebrain stimulation, and the CS was sleep preparatory behavior.  Sterman et al. used 
variation in tone frequencies, and the conditioned response showed variation in resulting 
behavior.  Other studies done on animals recently confirmed that monkeys and rodent were 
able to learn and modify their brain activity (Koralek et al., 2012) 
This was the beginning of a series of studies from healthy participants and animals 
studies that provided the rational to use it later to treat neurological conditions that will be 
described in further chapters specifically related with epilepsy.  
 
Types of Neurofeedback and Protocols 
Varying types of neurofeedback intervention have been studied for the last 40 years 
in the attempt to improve the clinical symptoms of seizures.  There are four main types of 
neurofeedback discussed in the literature.  Table 4 describes these types and their most 
common application.   
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Table 4   
Types of Neurofeedback and Clinical Applications 
Neurofeedback Type Channels Clinical Applications 
Frequency power  2-4 ADHD, anxiety, epilepsy, 
depression, insomnia, 
within others.   
Slow cortical potentials 4 ADHD, epilepsy and 
migraines 
Z score  2-19 Insomnia 
LORETA 19 Addictions, depression, 
obsessive-compulsive 
disorder 
 
The following sections explore frequency power (or sensory motor rhythm [SMR]) 
and slow cortical potentials neurofeedback in detail, as these comprise the two 
interventions investigated in this study.   
Another type of neurofeedback, Z-score neurofeedback is a continuous comparison 
of variables of brain activity to a database to deliver continuous feedback (Áine, Kate, 
Graham, Jamie, & Michael, 2014). And low-resolution electromagnetic tomography 
(LORETA) neurofeedback is based on source localization images that provide more 
specific training targets (Cannon et al., 2006).  As Table 4 illustrates, frequency power and 
slow cortical potentials are the types of neurofeedback that promise effects for epilepsy 
while the other types do not pertain to epilepsy.   
It is also important to acknowledge the different protocols used in frequency power 
neurofeedback.  The names of the protocols are based on the frequency bands that comprise 
the focus in reward specific frequency band training.  Table 5 shows the different protocols 
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that have been studied and the disorders they treat (Marzbani, Marateb, & Mansourian, 
2016).   
Table 5 
Frequency Power Neurofeedback Protocols and Indications 
Protocol Indications 
Delta Pain, sleep, headaches, emotional trauma, 
traumatic brain injury 
Theta Improve memory, promotes creativity 
meditation and improve sleep 
Alpha Pain, anxiety, improve memory, mental 
performance 
Alpha/Theta Anxiety, depression, addictions 
Beta/SMR Epilepsy, depression, sleep disorders, 
ADHD, improve cognitive process 
Gamma Improve memory and cognitive process 
 
Neurofeedback and Epilepsy 
Sensorimotor rhythms (SMR) and slow cortical potentials (SCPs) are two 
neurofeedback techniques that have demonstrated efficacy in dealing with epilepsy.  The 
neurophysiology and justification for the use of each method in relation to epilepsy will be 
presented in the sections below. In addition, this chapter includes the background on the 
effect of each neurofeedback technique on clinical improvements in epilepsy, as well as 
discussion of neurofeedback and cognition. These discussions support exploring broader 
the effects in cognitive function such as attention task in epilepsy.  
Sensorimotor Rhythm 
Sterman et al. (1969) initiated the first clinical application of operant conditioning 
of EEG and conducted a series of investigations to understand learned suppression of a 
response., while examining the learned suppression of this response, it was important that a 
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specific EEG rhythm of a sensory motor cortex appeared above non-rhythmic, low-voltage 
background activity.  This specific rhythm had a frequency of 12–20 Hz and spectral peak 
of 12–15 Hz, unlike any EEG sleep spindles.  In Figure 9, 12-15Hz was denoted as SMR. 
  
 
Figure 8. Electroencephalography samples from sensorimotor and parietal cortex in the cat during quiet 
wakefulness and quit non-Rem sleep.  Both stated are associated with burst of 12-15Hz (Sterman, Howe, & 
Macdonald, 1970). 
 
Neurophysiology of SMR.  The ventrobasal nucleus of the thalamus (nVB) forms 
the foundation of SMR and is responsible for conducting afferent somatosensory 
information (Sterman, 1972). Three types of neurons are known in the thalamic relay.  
First, thalamocortical neurons perform their functions in two different modes.  The first 
mode acts as a relay cell for transmitting and assimilating ascending sensory input by 
depolarizing input volleys.  In the second mode, it plays the role of an oscillatory cell by 
blocking the information from reaching the cortex while working in a collective rhythm 
(Lopes da Silva, Pijn, Velis, & Nijssen, 1997).  Second, reticular nucleus neurons are 
responsible for providing restricted (hyperpolarizing) feedback control to the 
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thalamocortical neurons.  Finally, local interneurons synchronize successful 
communications between thalamocortical neurons and the reticular nucleus (see Figure 10). 
 
Figure 9. Thalamocortical circuit diagram (Khosravani & Zamponi, 2006). 
 
The nVB firing patterns shift from fast and non-rhythmic (tonic) discharges to 
systematic, rhythmic bursts of discharges when conditioned SMR production takes place.  
Suppression of somatosensory information emerges from these discharges  coupled with a 
reduction in muscle tone (Howe, 1973). When afferent somatosensory input is reduced, the 
nVB cells also hyperpolarize.  A gradual depolarization is mediated by a slow calcium 
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influx that causes nVB neurons to discharge a burst of spikes.  This is carried out to 
stabilize the level of inhibition.  Thereafter, neuronal networks are connected to thalamic 
reticular nucleus (nRT) neurons and to the sensorimotor cortex.  Additionally, if stimulated, 
the latter then leads to a GABAergic inhibition of VB relay cells, and again returns to a 
hyperpolarized state.  Hence, a new cycle of slow depolarization will be initiated.   
Rhythmic thalamocortical volleys and consequent cortical EEG oscillations occur 
when neuronal populations in the nVB, nRT and sensorimotor cortex are interrelated with 
each other (Sterman & Egner, 2006).  The oscillatory activity is largely influenced by 
nonspecific cholinergic and monoaminergic neuromodulation. In addition, SMR is initiated 
when the efferent motor and afferent somatosensory activity are reduced.  
Comprehensively, neurotransmitters affect excitability levels of both the thalamic relay 
nuclei and the cortical areas that receive the relay signals.  When a person walks, the 
neuromodulatory influences cortical projections and the nVB cells are depolarized.  Also, 
the rhythmic bursting patterns are suppressed.  Meanwhile, oscillations at SMR frequency 
are observed during behavioral stillness.  Thus, SMR constitutes the dominant frequency of 
the integrated thalamocortical, somatosensory and somatomotor pathways.   
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Figure 10. Overview of the neurophysiological changes associated with trained burst of the sensory motor 
rhythm in a cat. 
 
Figure 10 illustrates an overview of the neurophysiological changes associated with 
a trained burst of SMR rhythm in a cat.  On the effect side of the motor pathway, an abrupt 
decrease in muscle tone is seen together with a corresponding decrease in the firing rate of 
cells in the red nucleus and a suppression of the monosynaptic stretch reflex excitability.  
On the afferent side of the somatosensory pathways, a decrease in the firing rate of somatic 
afferent cells is accompanied by a shift to an interactive burst-silence pattern in cells of 
both the somatosensory relay nucleus of the thalamus and the thalamic nucleus reticularis, 
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resulting in rhythmic oscillation that can be recorded over the sensory cortex (Egner & 
Sterman, 2006).   
Egner and Sterman (2006) related the production of field potentials at scalp level 
that exert influence on the thalamus with three integrative activities of the brain: vigilance, 
sensorimotor integration and cognitive integration.  The vigilance system was coupled with 
diffused networks and specific centres in the brainstem.  This system ascended and 
influenced the thalamic, subcortical and cortical centres.  The sensorimotor system 
involved ascending touch and proprioceptive pathways and their projections to the 
thalamus and sensorimotor cortex, and the efferent from this cortical area.  The vigilance 
system produced SMR, the 12–14 Hz rhythm over the sensorimotor strip.  Cognitive 
integration involved a range of activities that process and integrate sensory inputs and 
motor responses (Egner & Sterman, 2006). 
Egner and Sterman (2006) linked production of SMR, alpha and theta rhythms with 
the presence or absence of input, which arise from these systems on the thalamic oscillatory 
generators.  When the influence of combinations of the three modalities is withdrawn from 
thalamus, then different oscillatory modes appear in it.  Some prominent examples of the 
prototype involve initiating alpha rhythms by withdrawing brainstem cholinergic activity 
from the thalamus.  The SMR rhythm appears when sensorimotor inputs are withdrawn 
from it.  If cognitive processing is reduced (i.e., relaxed states without cognitive activity), 
then alpha appears.  Furthermore, if vigilance is withdrawn (i.e., states of inattentive 
drowsiness), then theta appears.  Thus, the underlying brain states of vigilance, cognitive 
processing and sensorimotor integration are attributed to the presence of these rhythms on 
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the EEG.  Hence, it can be assumed that attentiveness intrinsically accompanies various 
conditions of SMR-associated stillness (including frequencies between 15–20 Hz) 
(Abarbanel, 2009). 
SMR and Epilepsy 
Tan et al. (2009) conducted a meta-analysis focused on analysing index studies 
using neurofeedback in epilepsy in various databases between 1990 and 2005.  From 63 
published studies, only 10 met the inclusion and exclusion criteria (i.e., were peer-review 
journal publications, provided full information on patient selection, utilized SMR or SCP 
and reported individual pre- and post-treatment seizure rates).  These studies showed 
consistent positive results in treating refractory epilepsy participants.  All studies reported 
decreased seizure incidence resulting from neurofeedback.  The authors found that 64 out 
of 87 participants (74%) reported a reduction in weekly seizures.  As the study involved 
small groups, sample heterogeneity was possible (Q test, p = .18), random effects were 
assumed, and the effect of intervention was statistically significant (Tan et al., 2009).  Since 
Tan et al.’s meta-analysis, little research has been conducted on neurofeedback and 
epilepsy, mostly due difficulties in the methodology in a clinical trial for epilepsy 
applications.  
It is important to describe the first studies done by Sterman et al. (1969).  After his 
study showing that a cat could learn to modify brain activity, Sterman started a non-related 
study to establish dose-response functions of highly epileptogenic fuel compounds and used 
cats that had previously participated in SMR conditioning.  These cats displayed elevated 
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epileptic seizure threshold when compared to untrained animals.  The results suggested that 
SMR training inoculated the cats in avoiding seizures (Goff, Sterman, & Allison, 1966) 
Subsequently, Sterman and Friar (1972) studied applied EEG operant conditioning 
to treat clinical disorders. The authors described a twenty-three-year-old female with a 
seven-year history of generalized tonic-clonic seizures.  The patient encountered at least 
two major motor seizures per month.  When three months training enhancement of 12-15 
Hz was provided pertaining to EEG operant conditioning, the patient reported that the 
seizures terminated.  Additionally, quantitative analysis of the EEG over this period 
disclosed a significant increase of the 12–15 Hz band and a corresponding decrease in 
slower activity.  Hence, this patient was treated keeping in mind the requirements of an 
expanded multi-participant study.  Finally, the patient was seizure free and her medications 
were reduced.  Following the same authors, recruit another eight patients with intractable 
epilepsy (Sterman & Friar, 1972). The training aimed at increasing their production of 
SMR activity, but also added an inhibition training of 4-7 Hz slow-wave activities.  The 
participants’ seizures were focal and after treating the participants for six to eight months, 
their medication was adjusted according to their condition at the end of the trial.  Six out of 
eight patients reported post-conditioning reduction in seizure frequency; unfortunately, we 
can discuss here that the medications were adjusted, so the results may be questionable. 
Several other authors have published interesting findings, which is illustrated in 
Table 6.  In a recent review, Marzbani et al. (2016) summarized studies that were done on 
neurofeedback and epilepsy. All these studies showed 60-83% improvements in seizure 
reduction in patients with epilepsy.  Although these studies were conducted on different 
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types of epilepsy (focal and or generalized), and medications were modified during the 
intervention, as well as other methodology limitations, we have enough information and 
valid rational to continue exploring this intervention in epilepsy.  This study differs in that 
it explored a younger population. 
Table 6 
Summary of Neurofeedback Treatment Studies on Epilepsy 
Protocol Neurofeedback 
protocol 
Measuring 
results 
Length of 
treatment 
Age range 
(Sterman, 
Mcdonald, & 
Stone, 1974) 
SMR (11-15Hz) Seizure 
frequency, 
EEG 
6-18 months 6-46 
(Kaplan, 1975) SMR Seizure 
frequency 
20-25 weeks 20-30 
(Lubar & Bahler, 
1976) 
SMR Seizure 
frequency 
80-260 days 12-29 
(Kuhlman & 
Allison, 1977) 
SMR Seizure 
frequency, 
EEG 
24 sessions 17-42 
(Sterman & 
Mcdonald, 1978) 
SMR Seizure 
frequency 
12 months 10-40 
(Cott, Pavloski, & 
Black, 1979) 
SMR Seizure 
frequency, 
EEG 
210 days 16-31 
(Quy, Hutt, & 
Forrest, 1979) 
SMR Seizure 
frequency, 
EEG 
12 months 23-49 
(Lubar et al., 
1981) 
SMR Seizure 
frequency, 
EEG 
10 months 13-52 
(Tozzo, Elfner, & 
May, 1988) 
SMR Seizure 
frequency 
5 weeks 18-29 
(Lantz & Sterman, 
1988) 
SMR Seizure 
frequency 
8 months 18-45 
(Andrews & 
Schonfeld, 1992) 
SMR Seizure 
frequency 
6 months 20-40 
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SMR and Cognition 
After observing initial improvement in epileptic patients, the effect of SMR 
neurofeedback in attention processing and learning difficulties was studied in detail. Shouse 
and Lubar (1979) applied protocols that were similar to previous studies to reduce 
hyperactivity among hyperkinetic children, demonstrating the utility and success of 
theta/SMR neurofeedback for treating attention deficit hyperactivity disorder (ADHD) 
(Shouse & Lubar, 1979).  Lubar and Lubar (1984) also added beta (16–20Hz) to enhanced 
the attention.  According to Monastra, Lubar, and Linden (2001), the rationale for this 
treatment was that the children with ADHD displayed abnormally low beta and elevated 
theta activity.  
Additional studies have demonstrated that neurofeedback improves cognitive 
function in healthy individuals.  For example, Vernon et al. (2003) examined SMR training 
in medical students, finding that it improved their cognition when compared against another 
group trained to enhance theta (4–7 Hz).  The group that trained SMR showed development 
in semantic working memory and focused attention.  In a similar study, Egner and 
Gruzelier (2004) examined a group of participants to enhanced SMR and as a result these 
participants improved their perceptual sensitivity and reduced omission error and reaction 
time variability.  Moreover, the group that increased beta frequencies (15–18 Hz) witnessed 
improvement in their reaction time and the amplitude of P300 event-related potential 
(ERP).  Both studies demonstrated that the specific control groups did not encounter any 
improvement with these processes in contrast to the SMR groups.   
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Egner and Gruzelier (2004) also used this intervention in healthy patients, and 
found that enhancing SMR activity associated with lessening commission error and 
enhanced perceptual sensitivity on the Test of Variable of Attention (TOVA).  It also 
showed improvement in attention-related events and their associated potential.  The authors 
concluded that SMR neurofeedback enhanced the attentional process in healthy 
participants.   
As explained earlier, during the inactive focused and alert behavior, burst firing in 
the nVB to initiate SMR is done by attenuating somatosensory inputs.  Humans show 
greater activity in the 11–15 Hz frequencies in the somatosensory cortex when they visually 
pay attention to the stimuli compared to the completion of a motor task (Mann, Sterman, & 
Kaiser, 1996).  As a result, by suppressing SMR, an interference with perceptual and 
integrative competence of information processing occurs.  When SMR is conditioned, 
information processing decreases motor interference and improves cognitive functions 
(Vernon et al., 2003).  Haarmann, Cameron, and Rucjkin (2002) supported the finding that 
promoting brain activity ranging within 10–14 Hz is associated with semantic processing.  
Beyond the neurofeedback literature, cortical activity in the range of 10–14 Hz was 
associated with semantic processing. 
Slow Cortical Potentials 
The slow cortical potentials (SCPs) belong to the family of event-related potentials 
and are denominated as direct current (DC) (Olcese & Faraguna, 2015).  Unlike the 
oscillatory activity of the brain, evoked related potentials (ERPs) do not occur 
spontaneously, but over predictable a timeframe.  After the onset of the stimulus, SCPs can 
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be observed from 500 ms with a duration ranging from 300 ms to several seconds.  The 
timing of responding to a stimulus reveals various aspects of stimulus processing.   
Neurophysiology of SCP   
Walter (1967) first described the clinical significance of the contingent negative 
variation (CNV), which is the neurophysiological base of the SCP.  The author recorded 
DC potentials just one second before the stimulus was presented and pressed the button; 
this was preceded by warnings of the stimulus.  A slow change between the warning and 
the imperative stimulus was associated with amplitude coupled with behavioral significance 
(Walter, 1967).  Figure 11 illustrates various cortical activations, out of which C is the most 
significant and considered the SCP generator due the excitatory postsynaptic potentials 
(EPSPs) in the apical dendrites, which have their source in deeper layers near the soma and 
also involve long-distance connections.   
 
 
Figure 11. Diagram of four types of cortical activation (Müller-Preuss & Mitzdorf, 1984). 
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Potassium ions and glia also play a crucial role in the SCP generator.  Neurons 
liberate K+ so that the glial cells can be depolarized.  The SCP amplitude, extracellular K+ 
and depolarization glial are correlated and together represent neuronal activity.  Pre- and 
postsynaptic currents, EPSPs and IPSPs all summate in the SCP generator (Cordingley & 
Somjen, 1978).  Hence the SCP, which is close to the cell area, is generally produced by the 
neuroglia.  However, when the SCP has been recorded from human scalp, the contribution 
of the glial has been considerably small.  It is significant to consider the negative ions 
because they cannot cross the glial membrane.  The glial cells play an important role in 
determining volume conduction (Rockstroh et al., 1987).   
Additional neurochemical mechanisms are responsible for producing SCPs.  
Research has shown the role of dopaminergic and cholinergic projection to frontal 
neocortical regions in generating anticipatory negative SCPs (Bundy et al., 1980).  Some 
evidence has proven the need for catecholamines for generating SCPs at cortical sites; 
cortical negativity is also produced by the inhibitory activity of the GABAergic neurons in 
the reticular nucleus of the thalamus.  Reducing the activity of the dopaminergic-
noradrenergic further reduces tonic and phasic inhibition from GABAergic neurons, and 
finally produces positive SCP.  The implication of dopaminergic and cholinergic projection 
frontal neocortical regions in generating anticipatory negative SCPs has been observed 
form the evidence obtained from both humans and animals.   
Generally, SCPs fluctuate and vary from being electrically negative to positive.  
Negative surface SCPs are a consequence of synchronous slow excitatory postsynaptic 
potentials in the apical dendrites of Layer 1 in the cortex.  Positive fluctuations usually 
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represent the inhibition or reduction of prevailing negativities.  Electrical negative shifts 
reflect the activity occurring in the large cell assemblies that are also responsible for 
planning and initiating a goal-directed behavior.  In contrast, disfacilitation of excitation 
thresholds is considered as a positive shift in this direction (Haarmann et al., 2002).   
SCP and Epilepsy  
In order to understand the mechanism of SCP in epilepsy, we need to review the 
data on other neurological conditions.  A CNV of lower amplitude can be caused by general 
brain lesions.  Research has shown that the greater the brain damage, the lower the CNV 
amplitude (McCallum & Cummins, 1973).  The thalamus holds an important place in the 
producing SCP.  In one study, the SCPs were small or absent in a patient whose lesion 
invaded or distorted the thalamus (Purves & Low, 1978).  Research has additional shown a 
decrease in the CNV amplitude, either in depression or chronic anxiety in terms of mood 
disorders (McCallum & Walter, 1968). 
The epilepsy model of SCPs has demonstrated that the amplitude of surface 
negativity is dependent on synchronisation of the afferent input to apical dendrites.  
However, this “output positivity” may be compensated by continued simultaneous 
synchronous afferent input to apical dendrites (Strehl, Birkle, Wörz, & Kotchoubey, 2014).  
These results suggest that negativity is an indicator of cortical excitability.  In addition, the 
extreme potential amplitudes are related to overexcitability, which manifests itself in an 
epileptic seizure (Strehl et al., 2014). 
Rockstroh, Elbert, Lutzenberger, and Birbaumer (1979) reported on a study 
conducted with 25 patients suffering from epilepsy, and particularly partial seizures (though 
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some patients with primary generalized seizures were also included in the study).  Eighteen 
patients completed at least one year of follow up, and reported a significant decrease in 
seizure frequency when compared with baseline.  Six patients were seizure free, seven 
patients reported reduction in seizure frequency from baseline, and only five patients 
reported no change in the incidences of seizure (T.Elbert, B. Rockstroh, W. Lutzenberger, 
1980).   
In another study, Kotchoubey et al. (2001) used self-regulated cortical potentials to 
train patients suffering from intractable epilepsy.  The SCPs were compared with a new 
AED treatment and respiratory self-regulation.  The main seizure type was partial, but 
patients who suffered from absence, myoclonic, and primary generalised tonic-clonic 
seizures were also included in the study.  The results demonstrated a significant decrease in 
overall seizure rate for the SCP group and the antiepileptic group.  No significant 
differences were visible between the two groups.  Therefore, self-regulation of SCP was 
determined to be as effective a tool for controlling seizures as an addition to a new AED. 
Several studies have showed that training SCP has significantly improved cognitive 
functions.  In one study, when participants shifted between negative and positive SCP, they 
easily controlled their word processing (Pulvermuller, Mohr, Schleichert, & Veit, 2000), 
while the group that did not change their SCP did not report any development in their 
functionality (Vernon et al., 2003).  In another recent study, the results showed training 
SCP in patients with epilepsy could bring statistically significant enhancement in Global 
IQ, as compared to respiratory biofeedback and the control group  (Strehl, Kotchoubey, 
Martinetz, & Birbaumer, 2011). Finally, in the longest follow-up study conducted to date, 
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after being exposed to SCP neurofeedback, the findings of 6 out of 41 participants who 
completed the follow up showed that even after 10 years, seizure reduction was consistent 
(Strehl et al., 2014).   
SCP and Cognition  
SCPs are related to the attention preparation process.  After the stimulus is 
presented, the input can hold the information for a few milliseconds.  Thereafter, the pattern 
recognition filters the information in an evaluation process that registers the information in 
the long-term memory.  These concurring steps produce a first nonspecific response; these 
steps are not necessary for conscious awareness.  Preparation processes are viewed as 
facilitated performance (e.g., it shortens reaction time and increases error rate accuracy).   
A psychological description further clarifies the processing stages identified by 
cognitive experimentation, namely that SCPs play an important role from the second stage 
onwards.  Sensory and motor preparation are observed in due course in time and amplitude 
of negativity arising at 500 ms or later after presenting novel stimulus or the stimuli 
associated with response choices (automatized responses).   
A negative feedback loop limits the amount of negativity that a cortical network 
exhibits.  It produces or attenuates negativity after reaching a certain amplitude for a 
particular duration.  These limitations are dependent on both the anatomic localisation of 
the SCP generators and on the history of training a particular patient pertaining to that 
particular task.  Several studies have made use of two-stimulus designs coupled with 
varying difficulty of the related task.   
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Within the phasic tuning mechanisms, SCPs serve as a basis for attenuating 
regulation (Rockstroh et al., 1993).  A consistent relationship between cortical negativity, 
reaction time, signal detection and short-term memory performance have been found in 
several studies (Birbaumer, Elbert, Canavan, & Rockstroh, 1990).  Birbaumer et al. (1990) 
observed impaired regulation of SCP and reduced negativities in anticipating a task among 
children who suffer from attentional problems.  Strehl et al. (2014) found that ADHD 
children displayed reduced inactive state and low-frequency power (0.1 Hz) and attenuated 
power during rest-task transitions.  This varied significantly from healthy controls (Strehl et 
al., 2014).  Attenuation of power was negatively correlated to task performance, wherein 
participants who felt weak made the fewest errors (Strehl et al., 2014).  They exhibited 
variability and slower reaction times (Strehl et al., 2014).  The above findings also 
supported the conceptualization of ADHD symptoms in the form of impaired excitation 
threshold regulation, characterized by reduced cortical negativity (Strehl et al., 2014).  
Therefore, the authors hypothesized that training ADHD participants to increase their 
negative SCP would increase their capacity to produce cortical activation.  This mechanism 
was necessary for increasing their cognitive tasks and concentration (Strehl et al., 2014).   
Using SCP as a treatment parameter for children suffering from ADHD can lead to 
significant reductions in ADHD symptoms and improved attention.  It also produced 
changes in ERP and helped to obtain SCP feedback of the CNV.  Studer et al. (2014) found 
that after providing SCP feedback training, healthy participation from adults augmented 
their CNV amplitude.  Examination of EEG during SCP treatment also indicated that 
children suffering from ADHD could control SCPs.  This skill remained stable even after 
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the end of two years of treatment.  Neurofeedback therapy has proven to be an effective 
treatment for children; Studer et al. thus investigated whether SCP feedback can be an 
efficient treatment for adult ADHD participants. 
It is the purpose of this study to compare two neurofeedback modalities and explore 
the outcomes of each, in order to inform better decisions about which intervention is more 
appropriate for children who suffer from focal epilepsy. 
 
Conclusion 
It was important to consider the neurophysiology of each intervention and the type 
and nature of each participant’s epileptic symptoms.  The intention of the study was to 
explore the effects of two neurofeedback modalities in clinical, neurophysiological and 
cognitive outcome and to compare the two modalities of neurofeedback and is important to 
acknowledge the background that existed until now about the two neurofeedback 
modalities and their results in epilepsy and cognition. No previous studies compares the 
QOL on both types of neurofeedback.   
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Chapter 5    Methodology 
Participants 
The randomized controlled study included 44 participants (22 male, 22 female).  
These participants were chosen on the basis of the following criteria.  All participants were 
diagnosed with persistent focal epilepsy.  Focal epilepsy indicates that the seizures 
originate within networks usually limited to one hemisphere.  These seizures may be either 
discretely localized or more widely distributed (Berg & Millichap, 2013).  The participants 
suffered from at least one seizure in the previous 6 months (Loddenkemper et al., 2005).  
Third, their age ranged between 12 and 18 years (M = 14.8 years, SE = 2.28 years). 
Participants’ vision and hearing function was assessed using standardized tests, as this was 
an essential step in ascertaining the efficacy of the participants’ visual and auditory 
feedback stimuli.  The participants were asked to maintain stable doses of their medication 
throughout the trial and the subsequent 3-month follow up.  Individuals with other 
neurological disorders or decompensated illness (e.g., diabetes, renal failure) were excluded 
from the study.  Patients treated with Vigabatrin were excluded as this could lead to 
damage in visual processing  (Lüders, Turnbull, & Kaffashi, 2009). 
Participants were considered an opportunity sample in this study.  Four local 
neurologists referred study participants who completed the eligibility criteria (see Appendix 
B).  Those participants interested in being a part of the study received initial assessments.  
All evaluations were complete at the Biomedical Research Institute located in 
Aguascalientes, Mexico (see Appendix C). 
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Design 
This study employed a stratified, randomized, parallel trial.  Three homogenous 
groups of participants were categorized on the basis of their age and gender.  The first 
group was included in the SMR protocol, the second group was included in the SCP 
protocol, and the third group was included in the sham control protocol as independent 
variables.  The dependent variables were clinical, neurophysiological and cognitive 
measures. The clinical dependent variables were: seizure frequency (SF), seizure severity 
scale (SSS), and quality of life scale (QOLS).  The neurophysiological dependent variables 
included quantitative electroencephalogram (QEEG) that include four variables: theta 
absolute power, SMR absolute power, theta coherence and beta coherence; and cognitive 
dependent variables were the attention switching test (AST) that include four variables: 
letter category reaction time, letter category error rate, letter counting reaction time and 
letter counting error rate. 
Each participant  was evaluated at the beginning of the intervention (baseline), after 
the last session of intervention was concluded (after five weeks of treatment) and at 3 
months follow up, which is standard time for follow up in pharmacological studies (Pasha, 
Kamate, & Didagi, 2014).  Twenty-five one-hour sessions of neurofeedback were 
conducted in the protocol, as this is the minimum requirement to measure effect (Sterman, 
2000).  Each session was conducted from Monday to Friday for five consecutive weeks. 
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Figure 12. Participants (44 total) [SMR=Sensorimotor Rhythm; SCP=Slow Cortical Potentials. 
 
Figure 13. Design of the study. 
 
Figure 14. Items included on each evaluation. [SSS=Seizure severity scale QOL=Quality of life 
QEEG=Quantitative electroencephalography AST=Attention switching task SF= Seizure frequency]  
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Procedure 
Initial Assessment 
An interview was conducted at the initial assessment.  Background demographic 
information (e.g., data of birth, age and gender) was gathered.  All participants belonged to 
the same nationality (Mexican).  The potential participants also received complete medical 
and neurological examinations.  All available EEG and imaging studies were used in order 
to document the diagnosis of focal epilepsy.  In some cases, the localization of the foci was 
reported (see Appendix D).  All previous and current medication were documented 
including start dates and doses given to the patient.  At this point, the participants and their 
respective guardians signed the consent forms (see Appendices E & F).  During this 
process, the purpose of the study and potential benefits were explained in detail.  The 
participants were warned of potential risks in advance in order to avoid adverse reaction to 
the intervention.  Detailed information was given about the randomization strategy.  This 
strategy included the possibility of being assigned to a control group. 
 
Experimental Measures 
Clinical Measures 
All questionnaires and scales were completed in a quiet room and ample time was 
given to think about each response.  The primary care giver was responsible to respond to 
the questionnaires and scale.  It was requirement for the same person to answer the 
questionnaires and scales. 
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Seizure frequency.  Seizure frequency (SF) is considered the gold standard 
outcome when intervention in epilepsy is evaluated (Gilliam, 2002).  There are various 
scales to evaluate the outcome of epileptic seizure from the ILAE (Wieser et al., 2008).  For 
conducting evaluation on a year-by-year basis, the ILAE classification outcome assesses 
seizures per day instead of absolute number of seizures.  There is another classification 
known as Engel’s classification, which is used to assess postoperative outcome (Schachter 
& Schmidt, 1999).  For this reason, these classifications were not appropriate to accomplish 
the objective of this study, as none of the scales register intensity and duration of the 
seizures, which are components that would be important to consider in a clinical 
intervention for epilepsy.   
In this study, a seizure diary was included (see Appendix M).  To evaluate SF, a 
diary was used to record more detailed clinical information.  A format was designed for the 
diary wherein the parent or guardian could record the seizure experienced by the participant 
clinically during the period of assessment.  Details such as date, time of the day, and 
intensity, duration, and time of recording of each seizure could be recorded in this diary by 
the parent or guardian (see Appendix M).  Thereafter, the SF was compared during the 
intervention and follow up was provided to the participants.  No baseline SF was collected 
as the participants were from a low educational and socioeconomic status and did not have 
a reliable measure of seizures before the study.  Not all details mentioned in the diary were 
included in the data analysis. 
Seizure severity scale.  Seizure severity (SS) was evaluated by the revised 
Liverpool Seizure Severity Scale (Baker, Smith, Jacoby, Hayes, & Chadwick, 1998).  
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Chan, Zou, Wiebe, and Speechley (2015) demonstrated that the patients’ perceptions 
regarding the severity of their seizure could be more significant than the seizure frequency 
to determine his/her psychosocial wellbeing.  The rationale for including this scale in the 
study was due to the findings derived from previous studies that recommended evaluating 
the characteristics of the seizures.   
In the context of clinical treatment, 50% reduction of seizure frequency was 
considered a successful outcome for epilepsy treatment (Wirrell, Wong-Kisiel, & Nickels, 
2014).  Each patient classified their seizure differently on the basis of the severity.  Patients 
with severe epilepsy could distinguish between light and severe seizures using scales and 
by providing additional objective information (Smith, Baker, Dewey, Jacoby, & Chadwick, 
1991).  The Liverpool Seizure Severity Scale was used during this study to quantify the 
patients’ perceptions of the changed pattern of the severity of the seizures during the course 
of the clinical trial.  The Liverpool seizure severity scale consisted of 20 items in these 
categories: perception of control subscale (8 items) and perceived ictal/postictal severity 
subscale (11 items).  Each item was scored on a one to four-point Likert response scale.  
For the purpose of this study, the total score of the scale was analyzed (see Appendix N).  
The scale was developed on the assumption that seizure severity is comprised of two 
factors: the perception of the patients to gain control of their seizures, and the perceived 
severity of the ictal (during the event or seizure) and postictal (posterior to the event or 
seizure) phenomena.  
The post-ictal stage is a normal period that is dependent on the type of seizure and 
the transition from the ictal period.  This stage involves a variety of symptoms.  Brain 
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function might be low when the body recovers, or causes a prolonged period of 
unconsciousness that lasts from hours to days at a time.  This phase may be further 
followed by a period of stupor or sleep, and, in rare cases, a period of prolonged 
generalized weakness.  This condition is known as Todd’s paralysis (Urrestarazu et al., 
2002). 
The present study investigated post-ictal modification with neurofeedback 
interventions. In the clinical practice, patients with epilepsy felt more distress from post-
ictal disability in comparison to the seizure itself.  Patients who suffered from refractory 
epilepsy treated with neurofeedback reported improvements in the post-ictal state before 
they experienced reduction in their seizure frequency.  
The post-ictal state is considered the activity of inhibitory systems (adenosinergic 
systems, especially gamma-aminobutyric acid B receptors) that has been seen in the post-
ictal cortex of rats.  Also, there is intervention from the limbic system and the mu receptors 
(Kulick, Gutherz, Kondratyev, & Forcelli, 2014)  The thalamus is important because it 
provides evidence of the major thalamocortical network in the post-ictal state, which is 
associated with the loss of consciousness (Penfield & Paine, 1955).   
A previous section explained the role of the thalamo-cortical circuits during the 
neurofeedback intervention.  It was hypothesized that by regulating these systems and 
circuits, the exacerbation of post-ictal symptoms could be prevented.  Thus, there was a 
need to evaluate if neurofeedback can modify the severity of the post-ictal state.   
Quality of life.  Quality of life was evaluated by measuring and assessing the 
impact of the paediatric epilepsy scale (see Appendix O) (Camfield et al., 2001).  This scale 
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was comprised of an 11-item questionnaire that is typically used in clinical trials for 
anticonvulsants.  The children’s’ guardians completed the questionnaire in order to measure 
the effects of their child’s epilepsy on family life.  The Jacoby scale is the precursor to the 
used scale, and some paediatric modification was introduced in the Jacoby scale  (Kellett, 
Smith, Baker, & Chadwick, 1997). Each item on the questionnaire featured a severity score 
of 0 (not at all) to 3 (a lot).  The higher the score, the more negative the impact of the item.  
The total score was computed as a sum and average.  Items were categorized under various 
sections such as academic improvement, social adaptation and self-esteem.  The assessment 
was included in the protocol as it was necessary to evaluate the psychosocial impact of 
epilepsy after implementing the intervention.  Quality of life was also evaluated at baseline.  
In addition, a three-month follow-up visit was scheduled to detect differences among the 
QOL measures; this scale was not used immediately after the intervention as it was 
designed to be used after a three-month interval (Camfield et al., 2001). 
 
Neurophysiological Measures 
The EEG was recorded with a Neuronavigator 23-channel EEG amplifier along 
with an isolated computer interface (model NN-1 manufactures by J & J Engineering).  The 
signals obtained by the EEG acquisition system were amplified.  The signal was digitally 
processed by a quantitative topographic analysis system, band passed from 1-50Hz. This 
required an amplifier with specific features: good noise behavior, low leakage current, high 
common mode rejection ratio (CMRR), high input impedance, high power supply rejection 
ratio (PSRR), and high isolation mode rejection ratio (IMRR) (Binnie, 2003).   
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Data filters were required to analyze the data (high filter 50Hz, low filter 0.3Hz). 
Routine EEG is usually sampled at a frequency of ∼250 Hz to remove the power line 
artefacts (50 or 60 Hz) (Nuwer et al., 1998).  In order to record the EEG, a fitted electrode 
cap with leads was placed according to the International 10/20 System (see Appendix G).  
This system was applied to achieve a standardized 19-channel EEG recording.  A 
referential recording was performed using the linked earlobes (see Appendix H).   
Electrodes are found in varied shapes and sizes depending on the task or 
experimental conditions, such as surface electrodes, needle electrodes, sphenoid electrodes, 
subdural strip electrodes and depth electrodes.  The most commonly used electrodes are 
surface electrodes which were attached to the skin with gel to monitor routine clinical EEG 
(Tong & Thakor, 2009).  Before initiating the recording, an electrode impedance of less 
than five Kohms was required for all sites.  The EEG signals were digitized at a particular 
rate or above 256 samples per second, band-pass filter between 0.5 and 35 Hz and for 
subsequent analysis.  These responses could also be stored on a hard disk.  For ten minutes, 
the participants were seated in a comfortable reclining chair.  During this time, a recording 
was done with the participant’s eyes closed for five minutes, after which they were asked to 
open their eyes for another five minutes.   
QEEG analysis.  Data were subjected to artefact detection and supplemented by 
visual review offline.  The NeuroGuide database (Applied Neuroscience, Inc.) was used to 
analyse the artefact-free data (minimum 60 seconds) in offline mode.  In addition, the 
dynamic normative database transformed EEG epoch into FFT algorithm and coherence 
measures (see Appendix I).  The analysis was conducted using of absolute power on 
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Laplacian montage at Theta band (4–7Hz) and SMR band (12–15Hz) on central 
localization (Cz) of the sensorimotor area when the eyes were closed (see Appendices J–L).  
For all participants, during training the active electrode was placed on the Cz, for this 
reason the QEEG data analyzed on these sites.  
To evaluate this data, various descriptive and statistical displays were used such as 
absolute power, relative power and connectivity of each clinical band and single Hertz 
evaluation.  As a connectivity measure, the coherence within the Theta (4–7Hz) and Beta  
(12–15Hz) bands was calculated.  Thus, in this study, I measured the coherence as a 
connectivity measure.  Coherence measures the degree of association of frequency spectral 
between time series (Thornton, 2000).  Thus, coherence was often interpreted as a measure 
of coupling and functional association between the two regions of the brain (Nunez, 
Srinivasan, & Fields, 2015).  Coherence was considered a sensitive measure that revealed 
subtle aspects of the dynamic networks of the brain.  These networks complement the data 
obtained by power spectral analyzes.   
This study did not analyse frequencies greater than 40Hz, as the database used does 
not include analysis over 40 Hz.  
Cognitive Measures 
Attention switching test.  The capability to behave adaptively in a complex world 
is one of the most important components of evaluating intelligence (Huepe & Salas, 2013).  
Another important component is to evaluate the ability to filter out the most important 
information at a particular moment.  Additionally, attention is a cognitive function that can 
be used as an objective measure to assess the effectiveness of an intervention in the 
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treatment of a neurological condition.  Cognitive switching is part of everyday life tasks; 
each task requires an appropriate configuration of mental resources, which is accompanied 
by a procedural scheme or task set (Kimberg, Aguirre, & D’Esposito, 2000).  Furthermore, 
an external stimulus triggered by each task is presented in a combination of task set.  These 
tasks sets are first acquired by trial and error and, thereafter, are stored in the memory.  This 
technique requires a balance between endogenous control and exogenous influences; it 
further requires attention, classification, flexibility, and inhibition. As such, the switching 
task paradigm is used to evaluate effective and overall cognition such as attention, 
concentration, control, inhibition and memory (working memory), and hence provided a 
cognitive measure.  It could perform other executive functions such as planning, organizing 
and sequencing (Monsell, 2003).   
The attention-switching paradigm can evaluate the function of numerous regions of 
brain and especially the prefrontal cortex (specifically the medial and lateral regions).  This 
is the region in which the neurofeedback intervention was located in this study (Cz) for 
their high connectivity with thalamo-cortical circuits and their reduction of 
hyperexcitability.  For this reason, it is relevant to measure during this intervention a 
specific test that measure directly functions of specific structures of the brain.  
This study used the Cedrus Corporation developed SuperLab 4.0 software in 2007 
in San Pedro, CA, to conduct the experiments associated with attention switching in 60 
trials (group of letters).  A cue was presented to the participant (+ or ∆) before each 
stimulus.  The + cue referred to the letters; if the stimuli showed an even number of letters 
(2 or 4), the participant had to press “A” key; if the stimuli presented an odd number of 
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letters (3 or 5) then the participant was required to press “L” key.  The ∆ cue referred to the 
type of letter—if the stimulus presented a vowel, the participant was supposed to press the 
“A” key; if the stimuli presented a consonant, the participant was supposed to press the “L” 
key.  In each experiment, a random set of 30 even/odd and 30 vowel/consonant stimuli 
were presented.  The stimuli comprised of 250 Arial fonts.  To complete each experiment, 
an average duration of 2–3 minutes was allowed.  The sum and average of reaction time 
(RT) in milliseconds and error rate (ER) was measured for each experiment.  The even/odd 
numbers represented a letter-counting task and the vowel/consonants represented a letter-
category task.  
During this study, the test was administered in a silent room.  The participants were 
required to sit on a comfortable chair at a distance of 30 cm from a 38-cm diagonal screen.  
While being seated on the chair, they could rest their arms on a desk while having close 
proximity to the keyboard.  The instructions were provided clearly in detail until the 
participants understood all procedures involved in the intervention.  Ten introductory 
stimuli were presented as test for practice.  Once the participants completed the practice 
trial without any support, the actual test was performed.  Thereafter, the results were 
exported to a Microsoft Excel spreadsheet for further analysis. 
Intervention 
Bio-Graph Infiniti Software was modified to standardize the functions for all 
groups.  This software has the capability of capturing raw data to conduct accurate 
statistical analysis.  Hardware ProComp Infiniti encoder (Thought Technology Ltd, 
Montreal, Canada) was implemented to enhance its power and flexibility in real time and 
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also to gain computerized biofeedback and data acquisition.  Thus, in order to obtain the 
highest quality signal, this hardware enabled internal calibration.  Thought Technology 
developed NFB equipment for several research studies.  In addition, the technology also 
supported SCP intervention. 
Before initiating the session, the participants were asked to sit in a comfortable chair 
in the office.  The seizure diary was collected and the parents/guardians were asked if the 
participant reported any adverse reactions.  In the first training session, the parent or 
guardians were allowed to remain present in the room when the instructions were 
explained.  For the actual test, only the participant and technician were allowed in the room.  
Additionally, each time they earned points by accomplishing their expected goals, the 
participants were instructed to give to the stimuli to achieve their goals.  Participants sat 
one metre away from a computer monitor and completed 30 minutes of actual training.  The 
technician also allowed resting breaks for the participants to make sure that they remained 
attentive to the stimuli.   
SMR intervention.  Nuprep EEG skin prep gel from Weaver & Compan was use to 
prepare the skin to decrease impedance.  Subsequently, Ten20 conductive paste from 
Weaver & Company was use to attach electrodes to the scalp or earlobes.  Before training, 
impedance was less than 5 Khoms.  The active electrode was set up in Channel A of the 
Pro-Infiniti encoder.  The signal was amplified using the EEG-Z, and the electrode was 
located at Cz with reference to both earlobes.  The pre-set parameters were as follows: 
inhibit theta (4–7Hz) at least 20% below their threshold, reinforce SMR (12–15Hz) 80% of 
the time and inhibit high beta (25–35 Hz) at least 20% below their threshold.  A puzzle with 
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three bars representing each frequency band was used as a visual stimulus for the 
participants.  One piece of the puzzle was open, and bars turned green whenever the 
participant achieved the parameters for 0.5 seconds.  The auditory stimulus was a bell.  In 
addition, by opening up subsequent puzzles, the participant could see a numerical reward of 
the points they earned.  Samples of the screens are shown in Appendix T.  The participants 
received feedback on their performance at the end of each session.  The technician recorded 
the theta/SMR/high beta thresholds every five minutes and at the end of the session.  The 
total rewards per session was also recorded.  Recorded information was saved on a template 
in addition to the data for each session (see Appendix R).   
SCP intervention. The first channel was used to set up the Pro Infiniti encoder.  On 
the basis of previous research, the electrode was placed on Cz  (Gevensleben et al., 2014). 
The reference electrodes were placed on both earlobes with the EEG-Z3 sensor (amplifier).  
Hence, to identify muscle artefact of the flicker, a second electrode was placed on the 
temporal area, which did not interfere with the EEG signal.  Finally, as a reference the third 
electrode was placed on Pz.   
The first 15 sessions were at 1:1 channel that inhibited 50% of the stimuli and 
rewarded 50% of the rest.  The objective of this exercise was to allow a learning 
opportunity for the participants to control their inhibition and reward cortical shifts.  The 
channel changed to 3:1 after 15 sessions, inhibiting 66% and rewarding 33%.  Thereafter, 
the participant learned to inhibit negativity.  Each session consisted of 75 trials.  Appendix 
S illustrates the visual stimuli shown to the participants.  Each trial included a balloon 
going up the screen if the goal was to activate the stimulus, or a submarine going down if 
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the goal was to inhibit the stimulus (see Appendix S).  Baseline was recorded for two 
seconds and was followed by eight seconds of activation or inhibition training.  If the 
participants were able to achieve the goals, at the end of each trial, they received visual and 
auditory stimuli.  A few seconds were allowed between the test and trial.  Small breaks 
were available depending on the needs of each participant.  In order to remove muscle 
artefacts, participants were asked to avoid blinking during the 8-second trial.  Instead, they 
could blink or close their eyes between the trials.  Participants received feedback of their 
performance at the end of each session  (Kübler & Birbaumer, 2008). In each session, 
inhibitions, activations, and total rewards were record. 
Control intervention.  The procedure of the control group was identical to the 
SMR group except for the fact that every participant watched a pre-recorded session In 
every session, a different recording was shown (see Appendix T).  In order to prevent 
unblinding, all procedures including the set-up time were kept identical.  In this group, no 
information was recorded.  
Randomization 
Participants are categorized on the basis of their gender and were randomly assigned 
to one of the three groups in a ratio of 1:1:1. The research coordinator assigned the 
randomization sequence, and the researcher was blind during the experimental protocol. 
Treatment of Blinding 
Until the follow-up finished, the participants were blind to know which group they 
were assign.  The technicians and the coordinators were unblinded but the principal 
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investigator was blind while collecting and analyzing the data.  Real intervention was 
offered at the end of the trial to the control group. 
 
Statistical Analysis 
The study aim was to examine two neurofeedback techniques to explore their 
clinical, neurophysiological, and cognitive effects among children with focal epilepsy. The 
statistical analyses used IBM SPSS Version 20 (IBM Corp, New York, NY, 2012).  The 
data of each dependent variable was obtained in numerical data form.  The last observation 
carry forward as an imputation method and intention-to-treat analysis was adopted in this 
study.  A mixed 3x3 and 3x2 ANOVA was used with treatment as a between-participant 
variable with three levels (SMR, SCP, and control), and time as a within-participants 
variable with either two or three levels depending on the measure (pre-treatment, post-
treatment, and follow up).  A regression analysis was used to compare the changes in brain 
activity over the course of the session and Pearson correlation was to find association 
between neurofeedback learning and reaction time.  
Sample size was calculated, as no preliminary data in this particular population 
intervention was available.  The standard deviation estimated in the range/6 = 27/6 = 4.5, 
that is the total range of a Gaussian distribution was six standard deviations.  A sample size 
of 48 children had 80% power to detect a difference of 4.05 points between the groups 
when testing using repeated ANOVA’s at the 0.05 level of significance.  Thereafter, the 
participants’ demographic and baseline characteristics are summarized.  Trial competition, 
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withdrawal, exclusion, and protocol noncompliance were recorded.  All medical history, 
medical information, and any other relevant baseline information were recorded. 
 
Data Treatment 
During the study required security and confidentiality of data was considered. Data 
management are performed in accordance with regulatory requirements of the clinical 
setting.  This included the development and management of a database hosted in a locked 
external hard drive, administered by the research coordinator. 
 
Ethical Considerations 
The Ethics Committee of De Montfort University (United Kingdom) and the 
Biomedical Research Institute (Mexico) approved the study protocol (see Appendices U & 
V).  Before commencing the trial, guardians of the participants provided written and 
informed consent that were reviewed and approved by the Ethics Committee.  A signed and 
dated statement was sent to the research coordinator mentioning that the protocol was 
approved.  All participants were informed that they could cease their participation at any 
point of time.  Additionally, no compensation was offered for their participation.   
The information clearly explained that if participants experienced any adverse 
reactions then they would be notified by the investigator immediately and the participant 
would be remove from the study, and his or her neurologist would be informed.  Double 
copies of the consent forms were signed and the original copy rested with the participants’ 
guardian or parents.  The methodology of this study agreed to conduct this trial in 
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accordance with all laws, regulations and guidelines of the pertinent regulatory authorities 
by signing this clinical trial protocol.  The trial was conducted according to the ethical 
principles set forth in the Declaration of Helsinki and other local regulatory requirements.   
 
Conclusion 
The methodology was designed based on previous neurofeedback studies (Sterman, 
Strehl, Fernandez).  Rationale of the use of each measure was explained to fulfil the 
research questions and hypothesis. The procedures were covered on each of the 
neurofeedback interventions explaining in detail how every session was and how data was 
collected. In addition, the statistical analysis and ethical considerations are discussed. 
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Chapter 6    Results 
Demographics 
Forty-four participants completed the intervention and follow-up.  Details of the 
demographics are shown in Appendix D.  The summary in Table 7 illustrates that the 
groups were equally distributed on age, gender, and localization of the foci.   
Table 7  
Summary of Demographics: Gender, Age Mean (SD), Localization of the Epileptic Foci and 
ADE Monotherapy or Polytherapy  
 SMR SCP Control 
Male/female 7/8 9/7 6/7 
Age, years 14.8 (2.33) 14.8 (2.3) 15 (2.3) 
Foci UNK/localized 8/7 9/7 6/7 
ADE mono/poly 9/6 13/3 8/5 
 
 
Clinical Variables 
Seizure Frequency 
A 3 x 2 mixed ANOVA was used to compare the effects of interventions on seizure 
frequency for all groups. There were no significant main effects (p >.10) or interaction 
effects (p>.5). There was no main effect of time [F (1,41) = 1.88, MSe = 5.72, p = .18] or 
group [F (2,41) = 0.50, MSe = 90.39, p = .61]. 
There was no significant interaction effect [F (1,41) =0.58, MSe = 5.72, p = .57]. 
The seizure frequency post-intervention, and the follow-up mean scores of the SMR 
group, dropped from 3.60 (SD = 12.850) to 2.167 (SD= 7.71); the follow-up means scores 
for the SCP group decreased from 1.75 (SD =6.213) to 1.16 (SD =3.71); for the control 
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group, the follow-up means scores also dropped from 0.38 to .31, which was the lowest of 
the three groups.   
There was a consistent trend to reduction of seizures, being more prominent in the 
intervention groups (see Figure 16). 
 
 
 
Figure 16. Mean seizure frequency by group post/follow-up. The error bars indicate standard error of the means. 
 
Seizure Severity Scale 
A Friedman non-parametric test was use for ordinal scale to compare the results 
from the seizure severity scale across the three treatment time points (pre, post, and follow-
up).  The test showed no significant differences in the seizure severity scale on any group 
for SMR (χ2 =2.8, p =.247), SCP (χ2 =2.0, p = .368) and control group (χ2 =2.0, p = .368).  
There was a trend for the SMR group to present a reduction overtime of the seizure severity 
scale when compared with the SCP and control group that showed slight increase post-
intervention and follow-up (see Figure 17). 
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Figure 17. Means global seizure severity scale by groups pre/post/follow-up. The error bars indicate standard 
error of the means. 
 
Quality of Life  
A Wilcoxon-signed rank test, a non-parametric test for related samples, was used to 
compare the QOL score across two-time points (baseline and follow-up).  The test showed 
a significant improvement in the QOL score for SMR (Z=-3.035, p =.002), and this change 
represented 1 percentage point over QOL score.  The analysis revealed a significant 
improvement in the QOL score for SCP (Z =-3.416, p = .001), and the QOL score for the 
SCP group changed by 1.2 percentage points. For the control group, the analysis showed a 
significant improvement in the QOL score (Z =-2.762 p = .006), which changed by .92 
percentage points. Figure 18 illustrates the mean by group baseline/follow-up. 
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Figure 18. Graph of means QOL global score pre/follow-up by group. The error bars indicate standard error 
of the means, *statistical significant <.05. 
 
Neurophysiological Variables 
QEEG.  A 3 x 3 mixed ANOVA was conducted for theta and SMR absolute power, 
and for theta and beta coherence. For absolute power for theta there was no main effect of 
time [F (1,41) =2.370, MSe= p = 0.106], or group [F (2,82) =2.013, MSe= 936.22, p = 
.119].  There was no significant interaction [F (2,82) =0.119, MSe = 465.10, p = .119]. 
For absolute power for SMR there were no significant main effects (p >.10) or 
interaction effects (p>.5). There was no main effect of time [F (1,41) =1.944, MSe= 5.89,   
p = 0.156], or group [F (2,82) =1.233, MSe= 8.8, p =.305]. There was no significant 
interaction effect [F (1,41) =0.119, MSe = 7.2, p = .305]. 
For Theta coherence there were no significant main effects (p >.10) or interaction 
effects (p>.5). There was no effect of time [F (2,82) =3.57, MSe= 2.79, p = 0.03], or groups 
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[F (4,82) =.727, MSe= .56 p = 0.57]. There was no interaction effect [F (2,82) =.72, MSe= 
.781, p = 0.48]. 
For beta coherence there were no significant main effects (p >.10) or interaction 
effects (p>.5). There was no effect of time [F (2,82) =.765, MSe= 2.02, p = .53], or groups 
[F (1,41) = 2.26, MSe= .63, p = 0.802].  There was no interaction effect [F (2,82) =.765, 
MSe= 64.4,   p = .52].   
However, mean score for the SMR group showed a persistent decrease of the beta 
coherence throughout the intervention, while the other two groups responded in the 
opposite direction (post-treatment and then drop on the follow-up).  Even though this result 
did not reveal statistical significance, the trends for the SMR group were as expected (see 
Figure 19) the SCP and control group increased beta coherence post-intervention and 
reduced for the follow-up.  
 
  
 
Figure 19. Mean beta coherence by group. The error bars indicate standard error of the means.  
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Cognitive Variables 
 The attention switching task was divided into four variables: letter category reaction 
time, letter category error rate, letter counting reaction time, and letter counting error rate.  
A 3 x 3 mixed ANOVA was conduct in all these variables.  
For letter category reaction time within participants analysis showed a significant 
main effect of time [F (2,82) =7.043, MSe= 4.5, p = 0.006, ηp2=.147], and for participant 
group there was a significant main effect as well [F (4,82) =3.319, MSe=  .652, p = 0.046, 
ηp2=.139]. There was no significant interaction effect [F (2,82) =1.35  MSe=  .352, p = 
.269], 
There was a significant improvement from baseline to post-intervention (p=.015) 
and baseline of follow-up (p=.041).  The SMR group showed significant improvement in 
the letter category reaction time from baseline to post-intervention compared with the other 
groups (see Figure 20).  
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Figure 20. Total reaction time per trial by group. The error bars indicate standard error of the means. 
*statistical significant <.05. 
 
The letter counting reaction time showed no significant interaction on time [F 
(1,41) =1.028, p = 0.367, MSe= 22.2]; however, there was a significant interaction between 
groups [F (2,82) =11.346, MSe= 10.8 p = 0.000, ηp2=.217] and  no significance on the main 
effect F (2,82) =.737 MSe= 14.7 p = .569, ηp2=.139].  Average reaction times for pre-
intervention were significantly higher than the average reaction times for the post and 
follow-up timepoints.  The SMR group showed significant improvement in the letter 
counting reaction time from baseline to post-intervention compared with the other groups 
(see Figure 21). 
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Figure 21. Total reaction time per trial by group. The error bars indicate standard error of the means. 
*statistical significant <.05. 
 
Error rate in letter category there were no significant main effects (p >.10) or 
interaction effects (p>.5). There was no effect of time [F (1,41) =1.330, MSe=  52.6 ,p = 
0.276] or group [F (2,82) =.849, MSe= 13.6,  p = .482] or interaction effect [F (2,82) =.849, 
MSe= 16.05,  p = .482]. 
For Error rate in letter counting there were no significant main effects (p >.10) or 
interaction effects (p>.5). There was no effect of time  [F (1,41) =1.504, MSe=22.1, p = 
.228, ηp2=.0.35] or group [F (2,82) = 1.504, MSe= 10.8 ,p = .228, ηp2=.0.35]. However, 
there was a significant interaction effect [F (2,82) =.737, MSe= .564,  p = .035]. 
Neurofeedback Learning 
In the SMR group, the neurofeedback learning was measured using the mean 
absolute power of theta and SMR of each session (25 sessions).  This analysis explores the 
ability to learn to modify theta or SMR over sessions (reduce theta and increase SMR).  A 
0
500
1000
1500
2000
2500
3000
3500
4000
4500
SMR SCP CONTROL
To
ta
l R
T 
pe
r t
ria
l
Baseline Post-treatment Follow-up
EPILEPSY AND NEUROFEEDBACK  102 
regression analysis was used to evaluate the mean absolute power of theta over 25 sessions. 
As a group, sessions were not a significant predictor of theta absolute power showing a 
neutral relationship (p =.909) (see Figure 22). 
 
Figure 22.  Scatterplot showed a linear regression of mean absolute theta over 25 sessions of the SMR group.  
 
A regression analysis was used to evaluate the mean absolute power SMR over 25 
sessions.  As a group, sessions were not a significant predictor of SMR absolute power 
(p=.916).  Even though there was no positive correlation, the effect of the outliers showed 
an effect due the variability over session. In this analysis, all participants (responders and 
non-responders) were included (see Figure 23).  Only 50% of the participants were 
responders (participants that learn to modify their brain activity in the desired direction). 
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Figure 23. Scatterplot showed a linear regression of mean absolute SMR over 25 sessions of the SMR group.  
 
In the SCP group, the neurofeedback learning was measured using the success 
number of successful trials by session.  80% of the participants were responders in this 
group.  Regression analysis was used to evaluate the successful trial per session over 25 
sessions.  As a group, sessions were a significant predictor of total successful trials (p < 
.001).  This indicates that the phenomenon of learning acquisition over the sessions was 
present.  However, this information did not show significant improvements on other 
variables in the SCP group (see Figure 24). 
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Figure 24. Scatterplot showed a positive regression of mean absolute theta over 25 sessions of the SCP group.  
 
It is important to mention that the parameters used on the two groups are not equal 
as in SMR measures brain activity and the SCP is an objective reward.  
Associations Between Neurofeedback Learning and Cognitive Functions 
As only the SMR group showed the significant improvements in letter category 
reaction time improvement over time, the association between neurofeedback learning and 
cognitive function was analyzed in this group and this variable. 
For the SMR group the mean difference in Theta between the first and last session  
and the mean difference in reaction time between the baseline and follow-up session were 
correlated.  
Only theta showed a positive correlation (r= .949) between the relationship of theta 
and reaction time.  The correlation was significant (p = .017).  For the purpose of this 
correlation, only the participants who learned to reduce theta absolute power were included 
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(50% responders) (see Figure 25).  The correlation was weak to determine the relationship 
between SMR and average reaction time per trail (r=.063) (p = .846).  
 
 
Figure 25.  Scatterplot showed a positive correlation between the difference of average reaction time versus 
difference in theta.  
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Chapter 7   Discussion 
The objective of this study was to evaluate the effect of two different types of 
neurofeedback on children with focal epilepsy.  As was mentioned in the previous chapters, 
epilepsy is a complex condition with various comorbidities.  These issues are poorly 
addressed during medical treatment, and are far more devastating than the seizures 
themselves.  During this study, the exploratory outcomes where broader than those of 
previous studies of neurofeedback and epilepsy (Kotchoubey et al., 1996; Kotchoubey, 
Blankenhorn, Fröscher, Strehl, & Birbaumer, 1997; Nagai, 2011; Sterman & Egner, 2006;  
Strehl, et al., 2014).  The outcome of the present study expanded to clinical, 
neurophysiological, and cognitive measures comparing two neurofeedback modalities. 
 
Clinical Outcome 
Seizure Frequency  
The results demonstrated a positive but non-significant trend in the reduction of 
seizure frequency among the  groups. Although both active interventions showed a bigger 
reduction that the control group, the lack of statistical significance may be associated with 
the degree of variability in seizure events, which a minimum threshold in the number of 
seizures might be necessary to capture the real effect of the active interventions once the 
frequency is decrease.  These results  did not reach statistical significance in both active 
groups, even though a positive response was observed  in seizure frequency.  This could be 
a consequence of various factors: small sample size, standard protocol (reinforcing and 
inhibiting the same frequencies for all participants on the same location), number of 
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sessions, rate of non-responders, and the age of the participants. It is important to consider 
that the patients were exposed to research staff for a long period of time, hence leading to 
potential bounding and positive interactions between participant and researchers. All of this 
might have affected the development of placebo effect, which can be regarded as a form of 
“experimental subordination” consider when  the participant wants to please the researcher 
based on his own expectation towards the experiment in the relationship with the 
researchers themselves. (Kienle & Kiene, 1997). 
The clinical experience has shown that the more individualized the protocols are for 
patients with epilepsy, the more efficient and faster response to the intervention.  This study 
did not consider individualized protocols.  Previous research has utilized a standard 
protocol over the sensorimotor cortex (Tan et al., 2009). The number of sessions also can 
be a factor, even if most researchers suggested that 25 sessions could be enough to 
consolidate neural circuits, there are many other neurofeedback and epilepsy studies that 
did a long-term intervention (10-12 months) (Sterman & Egner, 2006).  The age of the 
participants in this study is younger than any other study that has been published with 
Neurofeedback and epilepsy (Schwartz, 1973).  The changes of brain activity and chemical 
changes through adolescent will be discussed below.  
For the clinical interpretation, to have a positive trend of in the reduction of seizures 
is an important factor and worth exploring.  Both active intervention groups showed a 
positive trend in seizure reduction that could be considered in future studies.  
Improvements of the control group is also expected, since the placebo effect of 
epilepsy is well known to be as high as 20%.  In addition, this effect is as high 45-62% in 
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other neurological conditions (Bittar & Nascimento, 2015).  The placebo effect observed 
during this study will be discussed in detail below.  
 
Seizure Severity 
The seizure severity did not demonstrate any statistically noteworthy variation 
among the groups due the same reasons mentioned above (small sample size; standard 
protocol, number of sessions, rate of non-responders and age of participants).  The SMR 
group exhibited a tendency of reduced severity in seizure shortly after the intervention was 
provided, and this status was maintained during the follow-up period.  Indicating that the 
effect of the neurophysiological process remained for many days after the intervention.  
Again, the modifications in the SCP were not evident, perhaps because of the underpower 
sample size, or because the participants were in controlled environment that involved 
pharmacological treatment.   
In addition, it was important to consider the impact of age on seizure severity and 
seizure frequency.  Previous studies included participants who fell into the adult age range 
while in this study included children suffering from epilepsy.  Evidence showed that 
variation of brain activity is maximized during adolescence.  Changes in white matter, grey 
matter, GABAergic systems and neurotransmitter systems are more evident in the age 
range of the participants in this study (Craiu, 2013).   
The clinical experience showed that when used individualized protocols the first 
improvement in seizures we can observe is the seizure severity.  In the following order; 
reduction of the post-ictal state, then more presence of aura or anticipation of the seizure so 
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the person can find a safe place to be during the seizure, finally a conscious control over the 
seizure, and seizure reduction as a result.  These are consistent clinical observations that are 
encouraging for future researchers to consider. 
Quality of Life 
One of the main objectives of any medical treatment should be to improve the daily 
life of those patients who suffer from a specific medical condition.  Patients with epilepsy 
undergo treatment not necessarily due the seizures but to improve their lives.   
Unfortunately, once the patient is seizure-free, their physician typically does not 
offer other interventions to improve their QOL.  Other interventions that can be offered 
include psychological, psychiatric, and social counselling.  The options for treatment 
should also include multidisciplinary work and early intervention.  Regrettably, as many 
cases are complicated, many institutions do not feel capable of providing treatment.  Few 
settings offer cognitive training as an important intervention to treat epilepsy (Vermeulen, 
Alpherts, & Aldenkamp, 1993).  It is important to notice how control or support in relation 
to emotional stress can dramatically improve the progress of epilepsy and  that a group 
therapy intervention can reduce SF up to 70% (Williams, Gold, Shrout, Shaffer, & Adams, 
1979).  Other researchers also found that psychoeducational intervention can reduce 
seizures (Oosterhuis, 1994).   
With this evidence, there is support for the importance of valuing all the aspects that 
a neurofeedback intervention can offer to a person with epilepsy.  Any other intervention 
treats single symptoms, while neurofeedback broadly treats comorbidities that affect 
epilepsy.   
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Jacoby et al. reviewed QOL in various AED studies and compared patients in 
standard or new epileptic drugs.  The study involved 2,437 participants and a two-year 
follow-up and did not find consistent differences in QOL outcomes between groups.  In 
addition, the authors found that the individual response to a drug is more important for 
QOL than type of drug given to the patient.  Also, proposed that the most significant 
improvement in QOL is the early withdrawal of medication after seizure remission, 
treatment for single seizure and early epilepsy (Jacoby et al., 2015) 
In this study, the results revealed a statistical significant improvement in QOL 
among the three intervention groups.  The QOL scale measured health, relationships, social 
life, academics, self-esteem, and family activities; even if the results only measure the sum 
of all of these, all areas were greatly improved in all three groups.  The control group 
showed significant improvement as the placebo effect was strong in relation to this 
variable.  
Previous studies exploring the effects of expensive interventions versus placebo-
controlled groups, have revealed strong placebo responses; for example in patients with 
knee osteoarthritis  and vertebral fractures (Moseley et al., 2002; Wali et al., 2017).  It is 
possible that expectations regarding treatment are affected by the exposure and presence of 
impressive and expensive medical apparatus.  These factors must have a profound influence 
on complex emotional and cognitive interactions to the point that pain is controlled and 
function improved even in the presence of structural and mechanical problems. It has been 
demonstrated that neural networks involving placebo responses extend its activation pattern 
beyond their anatomical and functional circuitry boundaries.  For instance, sham analgesic 
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interventions not only activate the rostral anterior cingulate and the periaqueductal grey 
area where analgesic opioid receptors are stimulated to promote analgesic responses, but 
also the dorsolateral prefrontal cortex and the nucleus accumbens where expectations and 
reward responses are modulated respectively (Zubieta & Stohler, 2009). The placebo effect 
will be discussed in further details later on.  
It is probable that a person diagnosed with epilepsy and treated with neurofeedback 
has would improve their QOL based on these results, and this can be considered an 
important contribution to the field and patients.  The QOL scale was measured only on two 
occasions as the specifications of the use of the scale is that cannot be used more often than 
three months apart.  The scales were compared three months after intervention and the 
improvements were significant.  
It is important to consider the factor of social desirability as in the consent form 
mentioned that the intervention may offer some improvements (T. J Kaptchuk et al., 2008).  
This is the likely reason why the control group had significant improvement in the QOL 
scale.  For a clinical trial, it is important to acknowledge the power of this effect and value 
it.  
There is a possibility that when participants attempted to recover function of the 
body organ that is responsible for their disability, and they actively work on this 
intervention, they can achieve a better QOL outcome in comparison to passive intervention 
(AED).  
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Neurophysiological Outcome 
Many researchers have studied the impact of neurofeedback on EEG.  All the 
studies addressed the behavioral outcome of the participants (Arns, Conners, & Kraemer, 
2013).  Thus, there emerged an understanding that when brain receives training, such action 
can be correlated with clinical outcomes.  Several researchers demonstrated that no 
significant changes in absolute power of the brain were seen, although improvement in 
coherence was observed (Mosanezhad Jeddi, & Nazari, 2013). Also they hypothesized that 
modification of coherence occurs prior to the modification of the absolute power.  This 
phenomenon occurs due to neuroplasticity through networks rather than in the single sites. 
Legarda, McMahon, Othmer, and Othmer (2011) proposed that the reinforcement challenge 
during neurofeedback aims to regulate the set point of arousal level in an individual.  It also 
aimed to reach a long-term stability in the habitual arousal state of individuals.  In this 
process, enhanced stability was accomplished because the challenge led to a system of 
resting state networks.  During this stage the nervous system network coherence was 
revealed when feedback was received while shifting the signals.   
The present study did not demonstrate statistical significant improvement either in 
absolute power or coherence; only the SMR group showed a positive trend on beta 
coherence.  This could be due to small sample seize, number of sessions, rate of non-
responders, age of participants, and standard protocol.  
Up to today, there is still a lot of controversy about the changes in, or improvement 
of, QEEG measure after neurofeedback (Simkin, 2016).  Empirical and clinical experience 
are showing that by using adequate procedures and analysis it is possible to achieve 
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changes in QEEG measures, for research purposes are more difficult to standardize this 
procedure.  
Cognitive Outcomes 
There are no therapeutic interventions for epilepsy that can impact more than one 
neurological symptom.  Seizure frequency can be reduced with AED, but other 
neurological and psychiatric side effects prevail.  In order to obtain productive and active 
life, cognitive enhancement is of utmost importance for epileptic patients.   
The active sensor was located in the primary sensorimotor cortex (Cz) among all the 
participants of the intervention groups.  Binkofski et al. (2002) showed functional studies 
confirmed that this particular region of brain was related to movement organisation, 
understanding, anticipation, organisation, planning, imitation, social behaviour, motor 
response, and inhibition.  All these functions are involved in performing attention switching 
tasks.   
The SMR group demonstrated significant improvement in reducing the reaction 
time of two variables; letter category and letter counting task, thereby showcasing 
improvement in time after the follow up.  The SCP and control group did not show this 
pattern.  This could be due to the technical limitations of the SCP procedure as explained 
below.  
It is important to mention here that the SMR group showed an advantage over the 
other two groups and placebo effect did not apply here as other variables did.  So, it has 
been demonstrated that the placebo effect is more evident in subjective measure than 
objective measures (Wechsler et al., 2011).  
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Neurofeedback Learning and Associations 
Even though it was not one of the objectives of this study, focusing on 
neurofeedback responders versus non-responders was important in order to separate them 
for the correlation analysis. In the SMR group, 50% were responders versus 80% in the 
SCP group; the parameter are not compatible, so it not possible to do an exact comparison 
for the two groups in this regard.  Even though the SCP group had more learners, it did not 
show statistical significance for any variable other than QOL.  This may be due the 
technical issues that are explained below in the limitation section. 
The only variable that showed significant positive correlation was the SMR group 
responders between the mean difference of absolute power theta over training and reaction 
time.  There was not a statistically significant correlation between SMR and reaction time 
and this can be due to neurophysiological effect that is evident during neurofeedback  
which is easier to learn to reduce theta than reinforce SMR (Mohammadi, Malmir, 
Khaleghi, & Aminiorani, 2015).  This positive correlation between reduction of absolute 
power theta over training with reduction of reaction time is what as expected 
neurophysiologically as theta can be a predictor of cognitive performance (Hermens et al., 
2005).  
 
Placebo 
The results showed statistically significant positive effects in the QOL measures in 
the control group. Placebo effects are known to be larger for medical devices and 
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technology and for invasive treatments (T J Kaptchuk, Goldman, Stone, & Stason, 2000) . 
Researchers have observed that various neurobiological and psychobiological mechanisms 
are involved in the placebo effect, especially through the neural circuitry associated with 
reward.  Furthermore, positive responses to placebo have been shown to involve networks 
associated with expectations to the treatment (Bittar & Nascimento, 2015; Colloca & 
Miller, 2011). Similarly, the two most prevalent psychological models that explain placebo 
effects are based on theories of expectancy and conditioning. Expectancy is usually thought 
of as a consciously accessible belief in the effectiveness of a therapy, while conditioning 
posits that previous experience taking (and benefitting from) effective medication or 
intervention (unconditioned stimulus) conditions an individual to experience benefit 
(conditioned response) in response to taking a pill or being exposed to a medical procedure 
(conditioned stimulus). These findings and models represent a complex system that 
responds and reacts to the presence of a fake or sham intervention (Albring et al., 2014).  
Jütte (2013) argued that since ancient times, the placebo effect recognized as an 
element of medical praxis.  Physicians from the Roman Empire knew that some bizarre 
forms of treatment were effective.  Treatment for epileptic seizures then included peculiar 
interventions such as pouring bile of dark vulture in old wine, or drinking blood mixed with 
incense, lamb bile, honey or ashes from a weasel.  Alternatively, rainwater collected in a 
human skullcap in supine position could be consumed. Seizures were also controlled by 
picking up pebbles from a swallows’ nest and hanging those pebbles around the neck of the 
person suffering from epilepsy.  Incredibly, all these treatments provided relief from 
seizures as reported in historic medical documents (Jütte, 2013).  
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What these bizarre treatments arguably represent is the construct of a healing ritual 
associated with the care of a malady (Ted J. Kaptchuk, 2002).  If the intervention has 
positive results, patients will associate that response with the ritual and the intervention.  
Thus, the conditioning goes beyond the simple act of drinking a repugnant pottage that may 
have a strong conditioning effect due to sensory overload, or to a very ineffective 
intervention such as collecting and drinking water in a skull.  Instead, the whole experience 
is enhanced by the complexity of the ritual, its symbols and human interaction with the 
healer. Medical rituals have a strong effect on therapeutic responses.  Studies in analgesia 
response have shown that hidden injections, which is when medication is administered by 
an automatized infusion pump, are significantly less effective and less variable compared 
with open injections in full view of the patient, suggesting that part of the clinical response 
and its variability was due to non-specific factors (exposure to the medical ritual of a nurse 
providing a painful injection to mitigate a painful condition) (Amanzio, Pollo, Maggi, & 
Benedetti, 2001; Colloca & Benedetti, 2005) .  
In the study reported here, it could be argued that both the real neurofeedback 
interventions and the sham group carried a strong medical ritual experience.  The 
experimental procedures represented the contemporary technological equivalent of an 
ancient remedy, and this resulted in expectations regarding the intervention that were 
similar to treatment expectancy observed in medical praxis. Moreover, the uncertainty of 
being randomized to either of the experimental groups may have influenced the response to 
subjective outcomes. Previous work showed that for patients with Parkinson’s disease, 
expectations of dopamine release enhanced reward learning and modulated learning-related 
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signals in the striatum and the ventromedial prefrontal cortex (Schmidt, Braun, Wager, & 
Shohamy, 2014). These effects were selective to learning from reward, showing that 
patient’s expectations shape their learning and affect their placebo response.  
Shapiro and Shapiro (2000) reviewed information regarding medication and 
procedures that were available across different historical eras, cultures, and societies.  The 
authors found that even bizarre medical interventions that remain ineffective were believed 
by patients to be effective.  This belief was reinforced with the event that comprised of real 
clinical improvements.  These improvements were seen as normal remission or progress of 
the illness itself among the epileptic patients.  When patients presented anxiety at that time 
the symptoms were relieved, or a true psychobiological placebo effect could be observed.   
The placebo effect is a positive outcome that results a sham intervention.  These 
improvements are a consequence of various factors, such as spontaneous improvement, 
statistical regression to the mean, psychosocial factors, biases, and co-interventions.  The 
real placebo effect is the significant improvement that occurs due to psychosocial factors 
(Finniss, Kaptchuk, Miller, & Benedetti, 2010).  Thus, it can be referred to as the 
improvement in the group that received placebo and can be elucidated that the placebo 
effect can improve the condition even if the cause is unknown to the patient.  It can be a 
spontaneous regression of the symptom, a real active involvement of the brain while it 
anticipates the outcome, or it might also represent a biased report of the patient who aims to 
please the doctor, researcher, or family members (Benedetti, 2014). 
Lately, many scientists have tried to distinguish the placebo effect from other 
phenomena that were observed in the clinical trials.  In modern medical practice, a placebo 
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effect is registered only when positive outcome is measured on a sham group.  Such studies 
emphasize the interaction between mind and body, a research area with particular 
significance in psychotherapy (Piersma & White, 1985).   
Brody (2000) defined the placebo effect as a change in the body, or the body-mind 
unit.  This effect occurred as a consequence of the symbolic significance which one 
attributed to an event or object in the healing environment (Brody, 2000).  The therapeutic 
context of placebo effect induced expectations which, in turn, gave rise to experience and 
behavior (Price et al., 1999).   
Understanding the placebo effect poses a challenge, because many mechanisms 
vary in the medical condition and therapeutic interventions.  When conscious physiological 
functions are involved, expectations and anticipations of clinical benefits become 
prominent.  Another crucial mechanism is anticipation of future outcomes (Tracey, 2010).  
Expectations drive cognitive readjustment of behavior.  Positive expectation is also 
involved in adopting particular behavior.  In addition, Staud and Price (2008) argue that 
memory, motivation, and the meaning of the experience related to illness prompt further 
expectations, leading to placebo effects.   
From a neuroscientific viewpoint, expectations of a future event are associated with 
many structures and process of the brain.  Neuronal networks of reward mechanism are 
linked with all types of responses, such as cognitive, emotional, and motor responses.  In 
order to modulate behavioral responses, dopaminergic cells in the brain’s ventral tegmental 
area are coupled with projections to the nucleus accumbens of the ventral basal ganglia that 
respond to the anticipated reward (Mogenson & Yang, 1991). 
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Any medical treatment or intervention that is performed in routine medical practice 
has two components, one related to the specific effects of the treatment itself and the other 
related to the perception that the therapy is being administered (Donald D Price, Finniss, & 
Benedetti, 2008). This is particularly the case when the therapy or intervention involves 
such a complicated set of processes as used in the current study, such as attaching 
electrodes to the head, calibrating computer software, presenting the animated stimulus 
with visual and auditory cues, and, importantly the constant presence of a therapist 
interacting with the patient. In this research protocol, the control group was presented with 
the same “rituals” of a modern technological therapy, and was also in the presence of  the 
research technician mimicking the application of what was supposed to be an active 
therapy. Today there is increasing evidence that beliefs and expectations, which are 
associated to the therapeutic procedure per se, can play a salient role in human health, and 
placebos can mimic, enhance, and mask the beneficial responses to pharmacological agents 
or medical interventions associated with technology (Benedetti & Amanzio, 2011). 
Arguably, the patient-technician interaction played a role in the psychosocial context 
around the experimental procedure. It seems reasonable that patients in the control group 
where not responding to the sham pre-recorded session presented on the computer screen, 
but rather, they were responding to the symbolic significance of being part of an 
experiment involving fancy technology. Moerman (Daniel E Moerman & Jonas, 2002) 
proposed replacing the term “placebo response” with “meaning response”, thus 
highlighting that what matters is not the inert treatment or sham intervention per se, but 
rather the meaning of the surrounding context and of the therapeutic ritual. This meaning 
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response is enhanced by patient’s beliefs and the expectancy that the intervention will 
provide a positive effect, a bias inherent in any clinical trial and a major source of 
“statistical noise” when comparing the effects of an intervention among experimental 
groups (D E Moerman & Jonas, 2000). Moreover, the human interaction associated with 
the experimental procedures might have had a special boosting effect on the placebo 
response, as patients with epilepsy usually are marginalized and disaffected. For such 
patients, a bonding with the experimenter might have served as surrogate of meaningful 
social relationship, otherwise not present in their daily life. 
It is important to consider that the strongest placebo response was observed in the 
QoL outcome, which is considered a subjective measurement and prone to be influenced by 
patient’s expectations and beliefs regarding the experimental procedures. In contrast, with 
other measures, specifically the objective measurements as in the case of physiological 
variables or cognitive performance metrics, the control group did not show that level of 
response when compared with the active interventions. The same degree of responsiveness 
to subjective measurements in the control or sham group can be observed on pain, anxiety, 
or sleep scales, but this effect disappears when objective measurements are applied.              
These findings demonstrated that a dynamic and “ritualistic” intervention may have 
a strong effect on the sham or control group, especially when parents are responding to the 
QoL questionnaire. It is not only these pediatric patients who are reporting improvements in 
their life, but also the parental perception of such improvements driven by their own 
expectations to the intervention generating a placebo by proxy response that has been 
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described in pediatric trials(Burkart et al., 2017) (Coghill, Banaschewski, Soutullo, 
Cottingham, & Zuddas, 2017).   
 
 
Placebo in Epilepsy 
Like other neurological diseases, epilepsy is a condition that is subject to placebo 
effect on randomized clinical trials. As is the case of increased placebo response observed 
in depression, anxiety and smoking cessation trials (Fava, Evins, Dorer, & Schoenfeld, 
2003).  Thus, a thoughtful approach to the placebo response and behavior in epilepsy is 
essential in order to explore the effectiveness of interventions among epileptic patients.   
Rheims, Cucherat, Arzimanoglou, and Ryvlin (2008) argue that regression to the 
mean may have had a significant effect on the outcomes of a study as participants may have 
been likely to enroll in trials when the seizure increased momentarily, and thereafter the 
seizures returned to baseline levels when the placebo or treatment had some effect.  There 
was evidence of the previous trial which mentioned that placebo response was more evident 
among children (Rheims et al., 2008). 
Goldenholz, Moss, Scott, Auh, and Theodore (2015) evaluated three major placebo 
mechanisms in epilepsy: regression to the mean (statistical phenomenon when a variable 
showed extreme results in the first measurement there is a tendency of the second 
measurement to be closer to the average), ongoing improvement (natural history of the 
disease), and information bias (individual interpretation of the information about the trail).  
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These researchers were able to gather more data about the effect of this mechanism of 
placebo in epilepsy and medical devices.  
The present study revealed a significant placebo effect with regard to QOL.  The 
QOL is a self-report measurement of wellbeing.  However, the results from this instrument 
are subjective and easily influenced by the responder’s physical and mental conditions at 
the time the questionnaire is being filled in.  The placebo effect is usually weaker when 
objective measurements are used as main outcomes. In a study investigating the effects of 
lidocaine injection for chronic lower-back pain, the sham injection group showed 
significantly better clinical responses, measured by the self-reported visual analog scale for 
pain (VAS), when compared to the standard treatment group (analgesic medication and 
physical therapy).  However, this effect reversed for the sham injection group when the 
outcome was the pain pressure threshold, which is an objective measurement of pain 
tolerance expressed in kilogram pressure force over square centimeter (Kgf/cm2) (Albring 
et al., 2014).  
If we consider those functions that affect the daily course of action when patients 
are diagnosed with epilepsy, then bringing improvement in them will be beneficial.   
There is evidence that the placebo has greater strength in comparison to medical 
devices than pharmaceutical interventions, as the participants were actually involved in 
activities that could improve their condition. This is another benefit of these interventions 
(Redberg, 2014). 
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Limitations of the Study 
The small sample size is a significant limitation of this study, as this is considered a 
pilot study that will require further trials.  There are other important limitations of the study 
design as some of the variables were measured only twice instead of three as the rest.  The 
population was of low socioeconomic status and did not provide information prior to the 
study. In addition, the participants had difficulties understanding the questions of the 
subjective questions measures and scales.  
Another significant limitation for the SCP group was differences in the 
methodology compared with previous SCP studies.  The average number of trials in 
previous SCP studies were 125 trials (Kotchoubey et al., 2001).  In the present study, the 
total training period was for 30 minutes and 75 trials.  The rationale for choosing this 
duration of training was that an average participant could remain attentive and cooperative 
only for 30 minutes.  Thus, only 75 trials per session were conducted for the purpose of this 
research.  In previous studies  sessions were arranged in blocks and homework was given to 
the participants of the study (Strehl et al., 2010).  There is a possibility that if the study had 
been conducted using more trials, then more modifications of these variables might have 
been observed.   
The present study used standardized neurofeedback protocols as previous 
researchers had done.  For future studies, it would be useful to consider individualized 
protocols for stronger effects.  It is also important to consider that not all the epilepsy foci 
were identifiable for this study.  This could be considered a weakness, which would suggest 
the inclusion of patients with well localized epilepsy foci, hopefully on the same location.  
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The consent form mentioned the possibility of experiencing benefits from 
participating in this study and could be considering a social desirability effect that affected 
the subjective measures.  This statement is part of the required consent form and ethical 
considerations during a clinical trial and thus cannot be excluded.  This factor of offering 
gentle attention, empathy, more duration of interaction are factors that are not avoidable 
and we expect some effect from them (T. J Kaptchuk et al., 2008) 
Another limitation of this study was the lack of measure for expectations. Boot, 
Simons, Stothart, & Stutts (2013) (Boot, Simons, Stothart, & Stutts, 2013) explain the 
failure to control for expectations is a common problem in mental health and cognitive 
studies. They propose alternative methodology designs to find clearly effects of the 
interventions  
 
Conclusions 
This research presented preliminary data comparing the effects of two 
neurofeedback modalities on children with focal epilepsy.  The novelty of this study was to 
broadly explore clinical, neurophysiological, and cognitive outcomes that no previous 
researchers have explored.  The age of the participants (children and adolescents) is a 
strength of this study as all previous research was done on adults. 
The first contribution to the field that it demonstrated that this is a safe, non-
pharmaceutical, non-invasive intervention that should be more explored as a treatment for 
epilepsy.  Safety is an important issue when considering a therapeutic intervention, and no 
side effects were reported during the study in any of the 44 patients,   
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The SMR group showed improvement in reaction time, which suggests that there is 
an effect on cognition that can be very helpful in everyday life activities.  Also, there was a 
positive improvement in the SMR group that were able to learn to modify their brain 
activity and improve the reaction time during the attention task.  Seizure frequency and 
seizure severity did not show statistically significant improvement, but it is important to 
mention that the trends were positive for the SMR group in these two variables. In addition, 
the seizure frequency did not increase, which illustrates the stability of epilepsy through the 
intervention.  Quality of life improved in all patients, including the control group, which 
could be due to a strong placebo effect. This study showed long lasting effects until the 
follow-up evaluation.  The results of this study also showed SMR neurofeedback has some 
advantages over SCP. 
Considering the few interventions to help comorbidities at the same time as seizure 
frequency it is important to continue exploring this intervention in larger groups of people 
with epilepsy at different ages and with different types of epilepsy.  Keeping in view the 
complexity of brain malfunction, there is also a need to try several interventions to improve 
comorbidities in epilepsy. More importantly, interventions should be developed that can 
help a patient and do not cause any harm to their well-being. 
Based on the results of this study, continued research on neurofeedback as an 
intervention to improve comorbidities in epilepsy would be beneficial.  
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Appendix A 
QEEG Analysis Method 
The QEEG analysis are classified in to linear and non-linear approaches, and there 
are dependants in which the analysis is based: time, frequency and time-frequency. 
In the following section the different theories are explained for deeper understanding 
of the analysis.  
Time Domain Methods 
The EEG signal can be analysed mathematically using different domains. The time 
domain in EEG modelling has been categorized in to two methods:  (Thakor & Tong, 
2004). 
a) Parametric methods: this method assume that the EEG signal created by 
equations, but with none define coefficients. The autoregressive model and the 
sinusoidal model are used for the analysis. The most known model of classical 
sinusoidal model is the Fourier transform (FT), which characterises the EEG 
with a series of waves 
b) Non parametric methods: This method studies directly the wave form by 
measuring the variety in amplitude. Another parameter to study is the wave 
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energy; there is a direct way to evaluate the strength change inside the signal 
(Abásolo, Simons, Morgado da Silva, Tononi, & Vyazovskiy, 2015). 
 
 
 
Frequency Analysis Methods 
EEG frequency analysis or also known as power spectral analysis.  The purpose is 
to divide the EEG signal in various frequency bands: Delta wave (0.5∼4 Hz), Theta 
wave (4–8 Hz), Alpha wave (8–12 Hz), Beta1 (12∼18 Hz), and Beta2 (18∼30 Hz).  
Spectral analysis has been in use as a diagnostic instrument. To measure the Spectral 
can find directly the PSD (power spectrum density) or the DFT (discrete fourier 
transform) which is fast algorithm of FFT (Juhász, Kamondi, & Szirmai, 2009). The 
power spectrum can be found by  
FFT-based spectral estimation is used then it is expected that the signal is stationary 
and do not change fast, and the limits ate the resolution and leakage effect 
(Muthuswamy & Thakor, 1998).  
 
Time-Frequency Analysis Methods 
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The EEG signal is active, time fluctuating, temporary (spikes/bursts).  These signals 
are, in general, non-stationary, and get disturbed by external noise. This analysis is needed 
due a pathological EEG.  
To analyse epileptic EEG time-frequency analysis should be used. For localization 
of the source there is the need to find the increase of time resolution and short time (STFT) 
to increase the time resolution; where the signal is first measured around a time instant t, 
and the Fourier transform is calculated for each time. STFT is based on FFT so that the 
time resolution does not continue elevated. STFT suffers from interchange between its 
window length and its frequency resolution. 
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Appendix B 
Criteria Checklist 
 
Participant_____________________________________   No._______________________ 
Inclusion Criteria Si No 
Participant must be on the age range of 12-18 years old   
Diagnosed with focal epilepsy   
Don’t have any other neurological disorder such as autism, ADHD, 
cerebral palsy, etc.   
  
Have at least 2 seizures in the last 6 months.     
Normal vision and audition   
Follow instructions    
No modification of medication during the trail and three months of 
follow up.   
  
Signed consent and assent form   
Availability for 25 sessions of intervention.  One hour Monday-
Friday)  
  
Exclusion Criteria   
Taking Vigabatrim   
Diagnosed with a systemic decompensated disease (diabetes, etc.)   
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Appendix C 
Initial Assessment Checklist 
 
 Participant ID  
 Initial Assessment Date 
 Introduction   
 Contact info  
 Clinical History  
 Medication  
 Criteria checklist  
 Preparation for the EEG  
 Consent forms  
 Neurological Evaluation  
 Review of medical records  
 EEG procedure  
 Attention switching test  
 Seizure diary  
 Protocol assignment  
 Head measurements  
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Appendix D 
Localisation of the Foci/Demographics 
 
 
Note: Condition, gender, age localization of the epilepsy foci (UN: unknown, TL: temporal left, TR: tempolra 
right, P:parietal), AED (NA: non, CBZ: carbamazepine, OX: oxacarbamazepine, VA: Valproate sodium, LV: 
levetiracepam PH; phenoberbital, LM: lamotrigine, DZ: diazepam). 
 
No. CONDITION GENDER AGE LOCALIZATION AED 1 D/24H AED2 D/24H AED3 D/24H
1 SMR M 18 UNK NA
2 SMR F 15 TL CBZ 600 LM 200
3 SMR M 13 TL OX 600
4 SMR F 17 UNK VA 1200 CBZ 900
5 SCP F 12 UNK VA 1500
6 SCP F 13 UNK VA 900 LV 2000 TP 300
7 Control M 12 TL VA 600 LM 200 CBZ 200
8 Control F 13 UNK VA 800
9 Control M 16 T/P CBZ 200 LV 1000 DZ 10
10 SMR F 14 T PH 100 LM 100
11 SCP M 18 UNK LV 1000
12 SMR F 12 P VA 800
13 SCP M 15 T VA 1200
14 Control M 12 P LM 200
15 SCP M 12 UNK NA
16 SCP M 12 T PH 800
17 SMR M 12 TL LV 1000 DZ 10 VA 600
18 SCP F 12 UNK VA 600
19 Control F 13 UNK VA 800
20 SMR M 18 UNK VA 800
21 SMR F 17 UNK VA 600
22 SCP M 14 UNK PH 200
23 SCP F 15 UNK VA 500
24 SMR M 16 TL VA 1400
25 Control F 18 UNK VA 400
26 Control F 18 UNK VA 800
27 Control F 14 T VA 600 OX 600 LV 1000
28 SMR F 18 UNK VA 600 LV 1000
29 SCP M 18 TL LV 1000
30 Control M 15 T VA 800 PHY 200
31 SMR M 13 UNK VA 400
32 SCP M 16 T CBZ 800 DZ 5
33 SCP F 14 T NA
34 SMR F 14 TL VA 600 CBZ 100
35 Control M 15 T LV 1000
36 SCP M 16 P VA 1200 CBZ 400
37 SMR M 13 UNK PH 200
38 SCP M 15 T VA 400
39 Control F 13 TR CBZ 200
40 SCP F 18 UNK VA 800
41 SCP F 18 UNK VA 1200
42 SMR F 12 UNK CBZ 250
43 Control F 18 UNK VA 600 CBZ 200
44 Control M 18 UNK CBZ 300
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Appendix E 
Consent Form 
Title: Effects of Sensory Motor Rhythm and Slow Cortical Potential Neurofeedback in 
Epilepsy: A comparative study  
 
Researcher: Principal Investigator: Diana Martinez, M.D., M.Sc. 
 
Aim: The purpose of the study is to investigate if there are any benefits of Neurofeedback 
in patients with epilepsy and compare the two modalities.   
 
Background: Previous studies have showed that the human i sable to learn how to control 
physiological functions such as blood pressure, heart rate, body temperature and brain 
activity.  Now we know that is possible for your son/daughter to learn to control their brain 
activity with an intervention known as Neurofeedback.  There are previous studies that 
doing such an epileptic patient can have some benefits.  But we are not sure how much or 
in which areas.  This is the reason why the investigator wants to ask for your permission so 
your son/daughter can participate in this study.   
 
Inclusion criteria: Your son/daughter need to fill the following requirement to participate.   
• Diagnosed with focal epilepsy.   
• Ages between 12-18 years-old. 
• Do not have any other neurological diagnosis (autism, developmental delay).  
• Normal hearing and vision.   
• No need of changes in medication during the trail and three months follow up.   
• Availability to complete 25 sessions of intervention.   
Exclusion Criteria:  
• If taking Vigabatrin. 
• Other neurological condition.   
 
Anticipated Benefits: It is important to understand that this is an investigation study and no 
a specific treatment for your son/daughter.  Even though, based in previous experience and 
research had showed improvements in patients with epilepsy.  If there are benefits with this 
collaboration Neurofeedback can be used for more patients with epilepsy.   
 
Procedures: Your child will be evaluated to begin the Neurofeedback intervention, at the 
end of 25 sessions and after three months of follow up.  These evaluations will include 
questionnaires, attention test and EEG.  You will need to fill a diary and bring it every day 
of session and during the follow up.   
 
During the Neurofeedback sessions your child will have some electrodes in the head, while 
they look to a screen; every time their brain activity works better they will see a visual and 
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auditory reward.  The total time of a session is 60 minutes including set up time.  None of 
these procedures are invasive.   
 
Three Study Groups: This study includes three groups.  Two of them will be exposing to 
one type of Neurofeedback and the third one will receive a sham intervention.  The 
assignation to the groups will be random and blinded to the principal investigator.  In case 
your child is in the sham group; Neurofeedback intervention can be provided at the end of 
the three months follow up at any cost.   
 
Possible Risks:  
• There are no significant or dangerous side effects for participating in this study. 
• The equipment doesn’t use electrical current to your child´s brain.   
• The electrodes in their head can be somehow uncomfortable.   
• There are some skins that can react to the contact of the electrodes.   
• Your child can experience some tiredness or light headache as if they just perform 
60 minutes of cognitive effort.   
 
Options to Reduce the Possible Inconveniences: The session will be terminated 
immediately if your child experiences any uncomfortable situation.  The session will 
continue only if your child feels normal and they agreed.   
The skin rash disappeared once the electrodes are removed.   
 
Alternatives to Participate: Be aware that there are other therapeutic alternatives for your 
son/daughter: 
• Antiepileptic drugs. 
• Surgery. 
• Vagal stimulator. 
• Ketogenic diet.   
 
Emergency: There will be emergency services if there is any situation that needed.  Not 
related illness need to be treated my physician.   
 
Compensation: This study does not offer any compensation to the participants.   
 
Privacy and Confidentiality: Only investigator of this study will review information about 
your son/daughter.  Any information will be share with other professions without your 
permission only if your child is at any risk of request for law.   
 
Participation and Termination: Your child participation in this study is voluntary.  If you 
chose not to let your child participate you are free to do so.  If you decide to participate you 
can stop at any time.   
 
Termination Consequences: There is any consequence if your child interrupts their 
participation in the study.   
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New Information: The investigator will communicate any new information about the results 
of the study or if there are other optional treatments for your son/daughter.   
 
Signing this form your child can interrupt their participating at any moment.  If you have 
any questions you can contact the investigator.   
Diana Martínez MD (researcher) Tel.  (449) 9180701 
 
I have read (or somebody read it to me) all the information in this form and I have asked all 
my questions.  All my questions have been answered.  I agreed my son/daughter will 
participate in this study.   
 
NAME SUBJECT_________________________________________________________ 
SIGNATURE_____________________________________________________________ 
DATE___________________________________________________________________ 
 
FATHER´S NAME_______________________________________________________ 
SIGNATURE_____________________________________________________________ 
DATE__________________________________________________________________ 
 
MOTHER´S NAME _____________________________________________________ 
SIGNATURE_____________________________________________________________ 
DATE_________________________________________________________________ 
 
WITNESS NO.  1__________________________________________________________ 
SIGNATURE_____________________________________________________________ 
DATE__________________________________________________________________ 
ADDRESS_______________________________________________________________ 
RELATION WITH 
SUBJECT__________________________________________________ 
 
WITNESS NO.  2__________________________________________________________ 
SIGNATURE_____________________________________________________________ 
DATE__________________________________________________________________ 
ADDRESS_______________________________________________________________ 
RELATION WITH 
SUBJECT__________________________________________________ 
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Appendix F 
Child Consent Form 
(For children 12 to 18 years-old) 
 
Dear _______________________________________________ 
       Name of participant 
    
The researcher of this study, Dr. Diana Martinez had explained to your parents about your 
participation in this project.   
 
The reason we call it project is because we are looking for what’s to find a new options to 
help your seizures and to improve your life.  We are not sure if we will be able to do it; this 
is why we call it research.   
 
We won’t ask you to do something that would be uncomfortable. 
 
You will wear a cap with some bottoms on the scalp; these bottoms will give us 
information about your brain and you will see in a screen some stimuli that you will learn 
how to manipulate them.   
 
The researchers will teach you how to do it.  This we call Neurofeedback.   
   
Please talk to your family member before you decide if you want to participate in this 
study.  We will ask your parents’ permission for your participation but you can decide.  If 
your parents said yes, you can say no.   
 
You don’t have to participate if you don’t want to; this is your own choice.  You can stop 
your participation at any time.   
 
You can ask all questions that you need and the researcher will help you at any time.   
 
Signing this you agreed with your participation in this study.   
 
Participant Name________________________________ 
Signature_______________________________________ 
Date___________________________________________ 
 
Witness No. 1 ___________________________________ 
Signature________________________________________ 
Date____________________________________________ 
Address_________________________________________ 
Relationship with participant________________________ 
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Witness No. 2 ___________________________________ 
Signature________________________________________ 
Date____________________________________________ 
Address_________________________________________ 
Relationship with participant________________________ 
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Appendix G 
Electrode Localisation 10/20 System 
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Appendix H 
Diagram of EEG Recording and Quantitative System 
 
Note: (I) Headstage and electrodes, (II) preprocessing and qEEG, and (III) data storage system.  The right 
bottom box illustrates the principle of rhythmical scalp EEG activities. 
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Appendix I 
FFT Coherence 
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Appendix J 
FFT Absolute Power (uA Sq) 
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Appendix K 
Z Score FFT Summary Map 
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Appendix L 
Screenshot Raw EEG, Spectral Absolute Power and Spectral Z Score Absolute Power 
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Appendix M 
Seizure Diary 
Date: 
Participant # 
Day  Frequency Duration Intensity Recovery 
1     
2     
3     
4     
5     
6     
7     
8     
9     
10     
Day  Frequency Duration Intensity Recovery 
1     
2     
3     
4     
5     
6     
7     
8     
9     
10     
Day  Frequency Duration Intensity Recovery 
1     
2     
3     
4     
5     
6     
7     
8     
9     
10     
Note: Frequency: How many seizures per day.  Parents need to list them individually, so they can describe the 
duration intensity and reco from each seizure.  Duration: Total time in seconds of the seizure.  Family 
members need to have a clock close all the time to time e seizure.  Include time of the day or night that the 
seizure happened.  Intensity: Rate the degree of each seizure from 0 to 5; being 5 the most intense seizure the 
participant has ever had and 0  weak.  Reco: Total time that the participant takes to recover all functions 
(language, mobility, behavior, attention, eye contact, awareness, etc).  This time includes any sleeping time 
the patient needed after the seizure.    
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Appendix N 
Liverpool Seizure Severity Scale 
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Appendix O 
Impact of Pediatric Epilepsy Scale 
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Appendix P 
Screenshot SuperLab Cue 
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Appendix Q 
Screenshot SuperLab Stimulus 
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Appendix R 
Session Registration 
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M
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S
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IO
S
Diario de 
convulsiones Comentarios
1
2
3
4
5
6
7
8
9
10
11
12
13
NÚMERO DE PARTICIPANTE
SESION Fecha
TH
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A
SM
R
M
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CU
LO
TH
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A
SM
R
M
ÚS
CU
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M
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CA
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S
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Diario de 
convulsiones Comentarios
14
15
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17
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INICIAL FINAL
INICIAL FINAL
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Appendix S 
Screenshot SCP Intervention 
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Appendix T 
Screenshot SMR and Control Intervention 
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Appendix U 
IRB Approval – Lic. González 
 
 
EPILEPSY AND NEUROFEEDBACK  187 
Appendix V 
IRB Approval – Dr. Morales 
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